# Title

 Food and Drugs. PART 314â€”APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG


# ID

 CFR-2018-title21-vol5.Pt. 314


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['greater', 'exceeds', 'more than', 'no later than', 'before', 'after', 'prior to', 'earlier than', 'less than', 'at least', 'exactly', 'within', 'exceed', 'later than', 'no more than', 'no earlier than']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Duration    | ['3.0 year', '45.0 day', '1.0 year', '180.0 day', '120.0 day', '2.0 month', '30.0 month', '5.0 year', '45 day', '4.0 year', '30.0 day', '3.0 month', '5.0 day', '2.0 day', '4.0 month', '90 day', '15.0 day', '14.0 day', '7.0 year', '10.0 year', '1 day', '90.0 day', '60.0 day', '20.0 day', '48.0 month', '6.0 month', '1 quarter']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Condition   | ['subject to', 'until', 'if not', 'as soon as', 'where', 'not subject to', 'when', 'provided that', 'unless', 'if']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Entities    | ['Pediatric', 'Efficacy', 'Important', 'Adulteration', 'Application', 'Routine', 'Original', 'Reference', 'Isolated', 'Bioavailability', 'Electronic', 'Review', 'English', 'Adequate', 'Rockville, MD', 'United States', 'Guidance', 'Followup', 'Serious', 'Applicant', 'G112', 'New', 'Docket Number', 'Specification', 'Adverse', 'First', 'Beltsville', 'Unique', 'Food', 'Refusal', 'Availability', 'Authorized', 'Dispute', 'Test', 'Research', 'U.S. Pharmacopeia', 'Correspondence', 'Washington, DC', 'Certain', 'Individual', 'Life', 'Patent', 'Request', 'Appropriate', 'Research, ATTN', 'Drug', 'Dosage', 'Same', 'Failure', 'Scope', 'U.S. Patent', 'Beltsville, MD', 'Bioequivalence', 'INDs', 'Documents, U.S. Government Printing Office, Washington, DC', 'Unexpected', 'U.S', 'Resubmission', 'Evidence', 'New Drug Quality Assessment', 'Petition', 'ICSRs', 'New Drugs', 'Effectiveness', 'Chemistry', 'Amendments', 'Appeals', 'Process', 'Strength', 'Judicial', 'Such', 'Disability', 'Research, Office', 'Active', 'Policy', 'Withdrawal', 'Approval', 'Change', 'Abbreviated', 'Tentative', 'Purchase', 'Agency', 'Purpose', 'Inactive', 'Health', 'Removal', 'Rm', 'Postmark'] |
| Date        | ['1984-09-24', '1999-01-01', '1938-06-25', '2010-01-25', '2050-05-01', '2018-05-06', '1971-02-01', '1962-10-10', '2018-03-01', '1975-07-01']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |


# Structured Analysis With Context

 


## Constraints

| Constraints     | Context                                                                                                                                           |
|:----------------|:--------------------------------------------------------------------------------------------------------------------------------------------------|
| before          | The 180-day period ends on the day  before the date on which an ANDA submitted by                                                                 |
| at least        | and Cosmetic Act for a drug for which at least some of the investigations described in section 505(b)(1)(A)                                       |
| before          | NDA or ANDA that must be satisfactorily addressed before  it can be approved.                                                                     |
| prior to        | (2) The physical form of the drug product prior to dispensing to the patient; (3) The way the                                                     |
| at least        | (8) Incorporate other information based on  at least  one adequate and well-controlled clinical study.                                            |
| greater         | analyses reveal risks of a different type or greater severity or frequency than previously included in submissions                                |
| after           | letter, or an NDA that was submitted again after  FDA had refused to file it or                                                                   |
| after           | letter, or an NDA that was submitted again after  FDA had refused to file it or                                                                   |
| before          | a complete response letter, but which was withdrawn before approval and later submitted again, is not a                                           |
| no earlier than | that the NDA or ANDA may be approved no earlier than  the date specified.                                                                         |
| after           | be approved until FDA issues an approval letter after any necessary additional review of the NDA or                                               |
| within          | not reside or have a place of business within the United States, the NDA is required to                                                           |
| within          | not reside or have a place of business within the United States, the NDA is required to                                                           |
| before          | manufacturing, and controls section 90 to 120 days before the anticipated submission of the remainder of the                                      |
| after           | applicant must submit these reports (1) 4 months after the initial submission; (2) in a resubmission following                                    |
| before          | regarding further details on its form and content. before                                                                                         |
| exceed          | drug, including a discussion of why the benefits exceed the risks under the conditions stated in the                                              |
| within          | applicant's failure to submit information requested by FDA within 30 days after receipt of the request may                                        |
| after           | submit information requested by FDA within 30 days after receipt of the request may result in the                                                 |
| before          | Applicants are invited to meet with FDA  before submitting an NDA to discuss the presentation and                                                 |
| within          | general requirements apply to the submission of information within the summary under paragraph (c) of this section                                |
| within          | general requirements apply to the submission of information within the summary under paragraph (c) of this section                                |
| within          | not reside or maintain a place of business within the United States, its attorney, agent, or other                                                |
| before          | (C) If,  before the date of submission of an original 505(b)(2)                                                                                   |
| within          | with FDA the required information on the patent within 30 days of issuance of the patent, an                                                      |
| before          | an applicant who submitted a 505(b)(2) application that, before the submission of the patent information, contained an                            |
| within          | of use claimed by the patent is submitted within 30 days of patent issuance; (B) The amendment                                                    |
| within          | of use claimed by the patent is submitted within 30 days of patent issuance; (B) The amendment                                                    |
| within          | of use claimed by the patent is submitted within 30 days of patent issuance; (B) The amendment                                                    |
| after           | (ii) An applicant whose 505(b)(2) application is submitted  after the NDA holder's untimely filing of patent information                          |
| before          | this section may be amended at any time before  the approval of the 505(b)(2) application.                                                        |
| after           | (i) After finding of infringement. after                                                                                                          |
| after           | a patent or patent information from the list. after                                                                                               |
| before          | submitted certification or statement if, at any time before the approval of the 505(b)(2) application, the applicant                              |
| after           | statement under paragraph (i)(1) of this section if, after submission of the 505(b)(2) application, a new patent                                  |
| after           | information on an otherwise applicable patent is submitted after  the approval of the 505(b)(2) application.                                      |
| prior to        | of exclusivity, it must submit with the NDA prior to approval the following information: (1) A statement that                                     |
| less than       | the applicant's financial contribution to the study is less than 50 percent or the applicant did not sponsor                                      |
| after           | Purchase of nonexclusive rights to a clinical investigation  after it is completed is not sufficient to satisfy                                   |
| within          | not reside or maintain a place of business within the United States, the NDA holder's attorney, agent,                                            |
| after           | by paragraph (a) of this section on or after the date of filing described in &#167;&#8201;314.101(a)(2) or                                        |
| later than      | in &#167;&#8201;314.101(a)(2) or (3), as applicable, but not later than 20 days after the date of the postmark                                    |
| after           | by paragraph (a) of this section on or after the date of filing described in &#167;&#8201;314.101(a)(2) or                                        |
| after           | in this paragraph (b) begins on the day after the date of the postmark on the paragraph                                                           |
| before          | this section is invalid if it is sent before the date of filing described in &#167;&#8201;314.101(a)(2) or,                                       |
| before          | this section is invalid if it is sent before the date of filing described in &#167;&#8201;314.101(a)(2) or,                                       |
| after           | (1) If,  after the date of filing described in &#167;&#8201;314.101(a)(2) or                                                                      |
| before          | (2) If,  before the date of filing described in &#167;&#8201;314.101(a)(2) or                                                                     |
| within          | The amendment must be submitted to FDA  within 30 days after the last date on which                                                               |
| after           | must be submitted to FDA within 30 days after the last date on which notice was received                                                          |
| after           | (f) Forty-five day period  after  receipt of notice.                                                                                              |
| within          | who resides or maintains a place of business within the United States authorized to receive notice of                                             |
| within          | who resides or maintains a place of business within the United States authorized to receive notice of                                             |
| after           | (ii) Submission of patent information upon and  after  approval.                                                                                  |
| after           | Within 30 days  after the date of approval of its NDA or                                                                                          |
| after           | information must also be submitted for patents issued after the date of approval of the NDA as                                                    |
| after           | be timely filed, patent information for patents issued after the date of approval of the NDA must                                                 |
| within          | of the NDA must be submitted to FDA within 30 days of the date of issuance of                                                                     |
| within          | If the applicant submits the required patent information  within the 30 days, but we notify an applicant                                          |
| within          | If the applicant submits the required patent information  within the 30 days, but we notify an applicant                                          |
| within          | who resides or maintains a place of business within the United States authorized to receive notice of                                             |
| within          | who resides or maintains a place of business within the United States authorized to receive notice of                                             |
| before          | product (formulation and composition), and method-of-use patent issued before the NDA is filed with FDA and for                                   |
| after           | If a patent is issued  after the NDA is filed with FDA but before                                                                                 |
| before          | after the NDA is filed with FDA but before the NDA is approved, the applicant must, within                                                        |
| within          | before the NDA is approved, the applicant must, within 30 days of the date of issuance of                                                         |
| after           | drug substance, drug product, or method of use after an NDA is approved, the applicant must submit                                                |
| within          | (d)(4) of this section, the required patent information within 30 days of the date of issuance of                                                 |
| within          | If the required patent information is not submitted  within 30 days of the issuance of the patent,                                                |
| after           | (ii) Patent information submitted upon and  after  approval of an NDA or supplement.                                                              |
| after           | its contents, i.e., &#8220;Patent Information,&#8221; or, if submitted after approval of an NDA, &#8220;Time Sensitive Patent Information.&#8221; |
| after           | the patent information is submitted by the applicant after approval of an NDA as provided under paragraph                                         |
| after           | the patent information is submitted by the applicant after approval of an NDA as provided under paragraph                                         |
| more than       | dispute must be only a narrative description (no more than 250 words) of the person's interpretation of the                                       |
| within          | in accordance with paragraph (f)(2) of this section within 30 days of the date on which the                                                       |
| more than       | of this section, provide a narrative description (no more than 250 words) of the NDA holder's interpretation of                                   |
| within          | verification required by paragraph (c)(2)(ii)(R) of this section within 30 days of the date on which the                                          |
| within          | verification required by paragraph (c)(2)(ii)(R) of this section within 30 days of the date on which the                                          |
| within          | verification required by paragraph (c)(2)(ii)(R) of this section within 30 days of the date on which the                                          |
| after           | (ii) Patent certification or statement during and  after  patent listing dispute.                                                                 |
| after           | listed patent, including the disputed patent, during and after  the patent listing dispute.                                                       |
| within          | NDA that includes a copy of the order, within 14 days of the date the order was                                                                   |
| after           | a paragraph IV certification to that patent or after the 180-day exclusivity period of a first applicant                                          |
| within          | This correction must be submitted  within 30 days of receipt of a certificate of                                                                  |
| before          | 505(b)(2) application is submitted; and (B) Was approved before  the original 505(b)(2) application was submitted.                                |
| less than       | made available to the site of action is less than that of the listed drug; or (2) The                                                             |
| less than       | made available to the site of action is less than that of the listed drug; or (2) The                                                             |
| after           | described in paragraph (a) of this section until after approval of the drug product for use in                                                    |
| before          | the drug is ready for approval in adults before studies in pediatric patients are complete, or pediatric                                          |
| within          | requirement that the applicant submit the required assessments within  a specified time.                                                          |
| within          | or resubmission of an NDA or efficacy supplement within 3 months of the end of the initial                                                        |
| more than       | or resubmission of an NDA or efficacy supplement more than 3 months before the end of the initial                                                 |
| before          | NDA or efficacy supplement more than 3 months before the end of the initial review cycle will                                                     |
| within          | of a major amendment to a manufacturing supplement within 2 months of the end of the initial                                                      |
| before          | holder must assess the effects of the change before distributing a drug product made with a manufacturing                                         |
| prior to        | of a supplement that does not require approval prior to distribution of the product or in an annual                                               |
| prior to        | (b) Changes requiring supplement submission and approval  prior to distribution of the product made using the change                              |
| prior to        | must obtain approval of a supplement from FDA prior to distribution of a drug product made using a                                                |
| at least        | Supplement-Expedited Review Requested.&#8221; (c) Changes requiring supplement submission at least 30 days prior to distribution of the drug      |
| prior to        | Changes requiring supplement submission at least 30 days prior to distribution of the drug product made using the                                 |
| less than       | product made using the change may begin not less than 30 days after receipt of the supplement by                                                  |
| after           | change may begin not less than 30 days after  receipt of the supplement by FDA.                                                                   |
| within          | the drug product made using the change if within 30 days following FDA's receipt of the supplement,                                               |
| prior to        | applicant that either: (i) The change requires approval prior to distribution of the drug product in accordance with                              |
| prior to        | change normally requiring a supplement submission and approval prior to distribution of the drug product that FDA specifically                    |
| within          | container closure system to another; (v) A change within the container closure system for a nonsterile drug                                       |
| prior to        | submitted as a supplement requiring approval from FDA prior to distribution of a drug product produced with the                                   |
| greater         | labeling, but differ from the event because of greater  severity or specificity.                                                                  |
| greater         | hepatic necrosis would be unexpected (by virtue of greater severity) if the labeling only referred to elevated                                    |
| greater         | cerebral vasculitis would be unexpected (by virtue of greater specificity) if the labeling only listed cerebral vascular                          |
| no later than   | foreign or domestic, as soon as possible but no later than 15 calendar days from initial receipt of the                                           |
| within          | 15-day Alert reports and must submit followup reports within 15 calendar days of receipt of new information                                       |
| within          | any appropriate means, each report to the applicant within 5 calendar days of initial receipt of the                                              |
| within          | The applicant must submit each quarterly report  within 30 days of the close of the quarter                                                       |
| within          | The applicant must submit each quarterly report  within 30 days of the close of the quarter                                                       |
| within          | (either individually or in one or more batches) within the timeframe specified in paragraph (c)(2)(i) of this                                     |
| after           | this chapter; (vii) Whether adverse drug experience abated after drug use stopped or dose reduced; (viii) Whether                                 |
| after           | this chapter; (vii) Whether adverse drug experience abated after drug use stopped or dose reduced; (viii) Whether                                 |
| more than       | to a drug for which an applicant holds more than one approved application, the applicant should submit the                                        |
| more than       | If a report refers to  more than one drug marketed by an applicant, the applicant                                                                 |
| within          | office that is responsible for the facility involved within  3 working days of receipt by the applicant.                                          |
| within          | The applicant shall submit each year  within 60 days of the anniversary date of U.S.                                                              |
| after           | The first annual report submitted on or  after January 25, 2010 must include the information listed                                               |
| after           | The first annual report submitted on or  after January 25, 2010 must include the information listed                                               |
| after           | (A study is considered completed 1 year  after  it is concluded.)                                                                                 |
| after           | product or a supplement to an application, or after  approval of the application or a supplement.                                                 |
| before          | The study was ended  before completion but a final study report has not                                                                           |
| at least        | the permanent discontinuance or interruption in manufacturing occurs. at least                                                                    |
| prior to        | review, and archive: (1) At least 6 months prior to the date of the permanent discontinuance or interruption                                      |
| later than      | soon as practicable thereafter, but in no case later than 5 business days after the permanent discontinuance or                                   |
| after           | months in advance, as soon as practicable there after , but in no case later than 5                                                               |
| later than      | (1) Not  later than 30 calendar days after the issuance of such                                                                                   |
| after           | (1) Not later than 30 calendar days  after the issuance of such a letter, the applicant                                                           |
| later than      | (1) Not  later than 30 calendar days after the issuance of such                                                                                   |
| after           | (1) Not later than 30 calendar days  after the issuance of such a letter, the applicant                                                           |
| after           | (1) Not later than 30 calendar days  after the issuance of such a letter, the applicant                                                           |
| within          | the demand or projected demand for the drug within the United States exceeds the supply of the                                                    |
| exceeds         | demand for the drug within the United States exceeds  the supply of the drug.                                                                     |
| more than       | of a drug by a manufacturer that is more than negligible and affects the ability of the manufacturer                                              |
| within          | expected to be no longer in commercial distribution. within                                                                                       |
| within          | in paragraphs (b)(3)(iv)(a)(1) through (4) of this section. within                                                                                |
| more than       | the applicant shall submit the information common to more than one application only to the application first approved,                            |
| within          | applications are suitable for the following drug products within the limits set forth under &#167;&#8201;314.93: (1) Drug                         |
| more than       | The petitioner may, under limited circumstances, identify  more than one listed drug, for example, when the proposed                              |
| no later than   | submitted, FDA will approve or disapprove the petition. no later than                                                                             |
| after           | (e) No later than 90 days  after the date a petition that is permitted under                                                                      |
| after           | (2) If,  after approval of a petition and before approval of                                                                                      |
| before          | (2) If, after approval of a petition and  before approval of an ANDA submitted pursuant to the                                                    |
| within          | not reside or maintain a place of business within the United States, its attorney, agent, or other                                                |
| within          | with FDA the required information on the patent within 30 days of issuance of the patent, an                                                      |
| before          | that contained an appropriate patent certification or statement before the submission of the patent information is not                            |
| within          | of use claimed by the patent is submitted within 30 days of patent issuance; (2) The amendment                                                    |
| within          | of use claimed by the patent is submitted within 30 days of patent issuance; (2) The amendment                                                    |
| within          | of use claimed by the patent is submitted within 30 days of patent issuance; (2) The amendment                                                    |
| after           | (B) An applicant whose ANDA is submitted  after the NDA holder's untimely filing of patent information,                                           |
| before          | this section may be amended at any time before  the approval of the ANDA.                                                                         |
| after           | (A) After finding of infringement. after                                                                                                          |
| after           | a patent or patent information from the list. after                                                                                               |
| after           | must submit an amendment to withdraw its certification. after                                                                                     |
| before          | submitted certification or statement if, at any time before the date of approval of the ANDA, the                                                 |
| after           | paragraph (a)(12)(i) and/or (iii) of this section if, after submission of the ANDA, a new patent is                                               |
| earlier than    | IV certification, the certification must not be submitted earlier than the first working day after the day the                                    |
| after           | be submitted earlier than the first working day after the day the patent is published in the                                                      |
| after           | a patent on the listed drug is submitted after  the approval of the ANDA.                                                                         |
| within          | not reside or maintain a place of business within the United States, the NDA holder's attorney, agent,                                            |
| after           | by paragraph (a) of this section on or after the date it receives a paragraph IV acknowledgment                                                   |
| later than      | paragraph IV acknowledgment letter from FDA, but not later than 20 days after the date of the postmark                                            |
| after           | by paragraph (a) of this section on or after the date it receives a paragraph IV acknowledgment                                                   |
| after           | in this paragraph (b) begins on the day after the date of the postmark on the paragraph                                                           |
| before          | this section is invalid if it is sent before the applicant's receipt of a paragraph IV acknowledgment                                             |
| before          | this section is invalid if it is sent before the applicant's receipt of a paragraph IV acknowledgment                                             |
| after           | acknowledgment letter, or before the first working day after the day the patent is published in the                                               |
| after           | (1) If,  after receipt of a paragraph IV acknowledgment letter or                                                                                 |
| before          | (2) If,  before receipt of a paragraph IV acknowledgment letter, an                                                                               |
| within          | The amendment must be submitted to FDA  within 30 days after the last date on which                                                               |
| after           | must be submitted to FDA within 30 days after the last date on which notice was received                                                          |
| after           | (f) Forty-five day period  after  receipt of notice.                                                                                              |
| before          | of an amendment containing significant data or information before the end of the initial review cycle constitutes                                 |
| no more than    | review the significant data or information and for no more than  180 days.                                                                        |
| before          | This paragraph (c) applies if, at any time  before the approval of the ANDA, a different listed                                                   |
| within          | as provided in paragraph (c) of this section, within 180 days of receipt of an application for                                                    |
| before          | the &#8220;initial review cycle.&#8221; (b) At any time before approval, an applicant may withdraw an application under                           |
| within          | will determine whether the NDA may be filed. within                                                                                               |
| after           | (1) Within 60 days  after FDA receives an NDA, the Agency will determine                                                                          |
| after           | of filing will be the date 60 days after  the date FDA received the NDA.                                                                          |
| within          | this section, the applicant may request in writing within 30 days of the date of the Agency's                                                     |
| after           | of filing will be the date 60 days after  the date the applicant requested the informal conference.                                               |
| after           | An ANDA will be evaluated  after it is submitted to determine whether the ANDA                                                                    |
| after           | which case FDA may consider the ANDA withdrawn after  1 year.                                                                                     |
| within          | NDA in response to a complete response letter. within                                                                                             |
| after           | (1) Within 180 days  after the date of filing, plus the period of                                                                                 |
| within          | FDA will either approve or disapprove the ANDA. within                                                                                            |
| after           | (2) Within 180 days  after the date of receipt, plus the period of                                                                                |
| before          | the review process and to submit an amendment before  the review period has elapsed.                                                              |
| after           | Approximately 90 days  after the agency receives the application, FDA will provide                                                                |
| before          | steps need to be taken by the applicant before  the application can be approved.                                                                  |
| after           | not be approved until FDA issues an approval after  any necessary additional review of the NDA.                                                   |
| exactly         | upon the applicant incorporating the specified labeling changes exactly as directed, and upon the applicant submitting to                         |
| prior to        | FDA a copy of the final printed labeling prior to  marketing.                                                                                     |
| after           | (c) FDA will approve an NDA  after it determines that the drug meets the statutory                                                                |
| after           | (c) FDA will approve an NDA  after it determines that the drug meets the statutory                                                                |
| after           | not be approved until FDA issues an approval after  any necessary additional review of the ANDA.                                                  |
| after           | (2) Patent information filed  after  submission of 505(b)(2) application or ANDA.                                                                 |
| after           | listed drug submits patent information required under &#167;&#8201;314.53 after the date on which the 505(b)(2) application or                    |
| before          | for which required information was submitted under &#167;&#8201;314.53 before the date on which the 505(b)(2) application or                      |
| within          | exclusive patent licensee brings suit for patent infringement within 45 days of receipt of the notice of                                          |
| after           | application or ANDA may be approved 30 months after the later of the date of the receipt                                                          |
| after           | application or ANDA may be approved 30 months after the later of the date of the receipt                                                          |
| within          | exclusive patent licensee brings suit for patent infringement within 45 days of receipt of the notice of                                          |
| before          | If  before the expiration of the 30-month period, or 71/2                                                                                         |
| before          | If  before the expiration of the 30-month period, or 71/2                                                                                         |
| before          | If  before the expiration of the 30-month period, or 71/2                                                                                         |
| no earlier than | the 505(b)(2) application or ANDA may be approved no earlier than the date specified by the district court in                                     |
| before          | If  before the expiration of the 30-month period, or 71/2                                                                                         |
| before          | If  before the expiration of the 30-month period, or 71/2                                                                                         |
| after           | ANDA may be approved any time on or after the date of the consent, approval may be                                                                |
| after           | ANDA may be approved any time on or after the date of the consent, approval may be                                                                |
| before          | If  before the expiration of the 30-month period, or 71/2                                                                                         |
| before          | If  before the expiration of the 30-month period, or 71/2                                                                                         |
| within          | in each pending suit for patent infringement brought within 45 days of receipt of the notice of                                                   |
| after           | application or ANDA may be approved on or after  the date of the order.                                                                           |
| within          | must submit correspondence to its ANDA notifying FDA within 30 days of the date of its first                                                      |
| within          | paragraph (e)(1)(i) of this section has been appealed within the time permitted for an appeal; (iii) A                                            |
| no earlier than | a 505(b)(2) application or ANDA may be approved no earlier than the date specified (irrespective of whether the injunction                        |
| within          | to the applicant's NDA or ANDA, as appropriate, within 14 days of the date of entry by                                                            |
| after           | (f) Forty-five day period  after receipt of notice of paragraph IV certification&#8212;(1) Computation                                            |
| after           | under &#167;&#8201;314.52 or &#167;&#8201;314.95 begins on the day after the date of receipt of the applicant's notice                            |
| within          | or ANDA applicant must notify FDA in writing within 14 days of the filing of any legal                                                            |
| within          | or ANDA applicant must notify FDA in writing within 14 days of the filing of any legal                                                            |
| before          | its representative(s) does not notify FDA in writing before the expiration of the 45-day time period or                                           |
| within          | a legal action for patent infringement was filed within 45 days of receipt of the notice of                                                       |
| within          | to file a legal action for patent infringement within 45 days of a receipt of the notice                                                          |
| before          | its representative(s)) submits to FDA a valid waiver before the 45 days elapse, the 505(b)(2) application or                                      |
| after           | submitted under section 505(b) and approved on or after October 10, 1962, or an application that was                                              |
| before          | applicant with regard to an investigation means that before or during the investigation, the applicant was named                                  |
| less than       | the applicant's financial contribution to the study is less than 50 percent or the applicant did not sponsor                                      |
| after           | Purchase of nonexclusive rights to a clinical investigation  after it is completed is not sufficient to satisfy                                   |
| after           | that contains a new chemical entity was approved after September 24, 1984, in an NDA submitted under                                              |
| after           | that contains a new chemical entity was approved after September 24, 1984, in an NDA submitted under                                              |
| after           | applicant during the 1-year period beginning 48 months after the date of approval of the NDA for                                                  |
| within          | the NDA for the new chemical entity and within 45 days after receipt of the notice described                                                      |
| after           | applicant during the 1-year period beginning 48 months after the date of approval of the NDA for                                                  |
| after           | Food, Drug, and Cosmetic Act; (ii) Was approved after September 24, 1984; (iii) Was for a drug                                                    |
| after           | Food, Drug, and Cosmetic Act; (ii) Was approved after September 24, 1984; (iii) Was for a drug                                                    |
| after           | (5) If a supplemental NDA:                                                                                                                        |
|                 |               (i) Was approved  after September 24, 1984; and (ii) Contained reports of                                                           |
| after           | (5) If a supplemental NDA:                                                                                                                        |
|                 |               (i) Was approved  after September 24, 1984; and (ii) Contained reports of                                                           |
| after           | If FDA determines,  after an application is filed or an abbreviated application                                                                   |
| after           | must take one of following actions: (1) Resubmission. after                                                                                       |
| within          | request for an opportunity for a hearing, or within a different time period to which FDA and                                                      |
| within          | applicant's failure to take any of such actions within 1 year after issuance of a complete response                                               |
| after           | take any of such actions within 1 year after issuance of a complete response letter to be                                                         |
| within          | consider an applicant's failure to resubmit the application within the extended time period or to request an                                      |
| within          | the applicant does not respond to the notification within 30 days, the application will be deemed to                                              |
| before          | evidence in the petition and any other evidence before the agency, and determine whether the listed drug                                          |
| before          | (ii) Was approved  before  the original 505(b)(2) application was submitted.                                                                      |
| at least        | least two doses of the drug are compared. at least                                                                                                |
| prior to        | with respect to a specific clinical investigation, either prior to the investigation or in the evaluation of a                                    |
| more than       | drug; (ii) If the reference listed drug has more than one active ingredient, information submitted with the ANDA                                  |
| more than       | drug; (ii) If the reference listed drug has more than one active ingredient, information submitted with the ANDA                                  |
| before          | a delivery or a modified release mechanism never before  approved for the drug.                                                                   |
| greater         | A change in composition to include a significantly greater content of one or more inactive ingredients than                                       |
| after           | the application or not available to FDA until after the application or abbreviated application was approved, or                                   |
| before          | (iii) Upon the basis of new information  before FDA with respect to the drug, evaluated together                                                  |
| within          | section 505(c) of the act was not submitted within 30 days after the receipt of written notice                                                    |
| after           | the act was not submitted within 30 days after the receipt of written notice from FDA specifying                                                  |
| before          | (2) That on the basis of new information  before FDA, evaluated together with the evidence available when                                         |
| within          | quality, and purity and were not made adequate within a reasonable time after receipt of written notice                                           |
| after           | were not made adequate within a reasonable time after  receipt of written notice from the agency.                                                 |
| before          | (3) That on the basis of new information  before FDA, evaluated together with the evidence available when                                         |
| within          | the labeling was not corrected by the applicant within a reasonable time after receipt of written notice                                          |
| after           | corrected by the applicant within a reasonable time after  receipt of written notice from the agency.                                             |
| after           | (i) A patent on the listed drug issued after approval of the abbreviated new drug application; or                                                 |
| after           | (i) A patent on the listed drug issued after approval of the abbreviated new drug application; or                                                 |
| within          | to whom the initial decision was sent may, within 30 days of the issuance of the initial                                                          |
| within          | (3) Comments and information received  within 30 days of the issuance of the initial                                                              |
| after           | be made by the agency at any time after the drug has been voluntarily withdrawn from sale,                                                        |
| prior to        | determination under &#167;&#167;&#8201;10.25(a) and 10.30 of this chapter. prior to                                                               |
| after           | effectiveness reasons may be made at any time after its removal from the list, upon the agency's                                                  |
| after           | to participate in a hearing, has 30 days after the date of publication of the notice to                                                           |
| within          | written notice of participation and request for hearing within  30 days, waives the opportunity for a hearing.                                    |
| within          | A person shall request an opinion  within 30 days of the date of publication of                                                                   |
| within          | 1061, Rockville, MD 20852, (i)  within 30 days after the date of the publication                                                                  |
| after           | 1061, Rockville, MD 20852, (i) within 30 days  after the date of the publication of the notice                                                    |
| within          | 1061, Rockville, MD 20852, (i)  within 30 days after the date of the publication                                                                  |
| after           | 1061, Rockville, MD 20852, (i) within 30 days  after the date of the publication of the notice                                                    |
| after           | FDA will not consider data or analyses submitted after 60 days in determining whether a hearing is                                                |
| before          | unless they are derived from well-controlled studies begun before the date of the notice of opportunity for                                       |
| within          | the results of the studies were not available within 60 days after the date of publication of                                                     |
| after           | FDA will not consider data or analyses submitted after 60 days in determining whether a hearing is                                                |
| within          | The comments are requested to be submitted  within the time and under the conditions specified in                                                 |
| within          | it is generally recognized as safe and effective within the meaning of section 201(p) of the act,                                                 |
| before          | the act under the exemption for products marketed before June 25, 1938, contained in section 201(p) of                                            |
| within          | product is generally recognized as safe and effective within the meaning of section 201(p) of the act                                             |
| before          | the act under the exemption for products marketed before June 25, 1938, contained in section 201(p) of                                            |
| after           | This person has 60 days  after receipt of the proposed order to respond with                                                                      |
| after           | The person has 60 days  after receipt of the proposed order to respond with                                                                       |
| within          | the Commissioner grants a hearing, it will begin within 90 days after the expiration of the time                                                  |
| after           | a hearing, it will begin within 90 days after the expiration of the time for requesting the                                                       |
| before          | the existence of an application or abbreviated application before an approval letter is sent to the applicant                                     |
| before          | abbreviated application has been publicly disclosed or acknowledged before the agency sends an approval letter to the                             |
| before          | abbreviated application has been publicly disclosed or acknowledged before the agency sends an approval letter to the                             |
| after           | unless the applicant shows that extraordinary circumstances exist. after                                                                          |
| before          | of the following: (i) For an application approved before July 1, 1975, internal agency records that describe                                      |
| after           | or internal reviews of the data and information, after deletion of the following: (a) Names and any                                               |
| after           | (ii) For an application approved on or  after July 1, 1975, a Summary Basis of Approval                                                           |
| before          | Evaluation and Research will review and may revise. before                                                                                        |
| within          | or study, unless it is shown to fall within the exemption established for trade secrets and confidential                                          |
| after           | consumer complaints, and other similar data and information after deletion of the following: (i) Names and any                                    |
| within          | or compliance purpose and is shown to fall within the exemption established for trade secrets and confidential                                    |
| after           | applicant which division is responsible for the application. after                                                                                |
| after           | required postmarketing study with due diligence; (3) Use after marketing demonstrates that postmarketing restrictions are inadequate to           |
| within          | to file a written request for a hearing within 15 days of receipt of the notice, the                                                              |
| within          | who requests a hearing under this section must, within 30 days of receipt of the notice of                                                        |
| before          | stay of action under &#167;&#8201;10.35 of this chapter. before                                                                                   |
| within          | well as advertisements, intended for dissemination or publication within  120 days following marketing approval.                                  |
| at least        | the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of                                        |
| prior to        | must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the                                     |
| after           | If FDA determines  after approval that the requirements established in &#167;&#8201;314.520, &#167;&#8201;314.530,                                |
| after           | and field trials to study the product's effectiveness after an accidental or hostile exposure have not been                                       |
| more than       | the product; (2) The effect is demonstrated in more than one animal species expected to react with a                                              |
| prior to        | with the product to be provided to patients prior to administration or dispensing of the drug product for                                         |
| after           | the postmarketing study with due diligence; (3) Use after marketing demonstrates that postmarketing restrictions are inadequate to                |
| within          | to file a written request for a hearing within 15 days of receipt of the notice, the                                                              |
| within          | who requests a hearing under this section must, within 30 days of receipt of the notice of                                                        |
| before          | stay of action under &#167;&#8201;10.35 of this chapter. before                                                                                   |
| within          | well as advertisements, intended for dissemination or publication within  120 days following marketing approval.                                  |
| at least        | the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of                                        |
| prior to        | must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the                                     |
| after           | If FDA determines  after approval under this subpart that the requirements established                                                            |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 180.0 day  | 180-day exclusivity period is the 180-day period beginning on the date of the first commercial marketing of the drug (including the commercial marketing of the reference listed drug) by any first applicant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 180.0 day  | 180-day exclusivity period is the 180-day period beginning on the date of the first commercial marketing of the drug (including the commercial marketing of the reference listed drug) by any first applicant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 180.0 day  | The 180-day period ends on the day before the date on which an ANDA submitted by an applicant other than a first applicant could be approved.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1 day      | First applicant is an ANDA applicant that, on the first day on which a substantially complete application containing a paragraph IV certification is submitted for approval of a drug, submits a substantially complete application that contains, and for which the applicant lawfully maintains, a paragraph IV certification for the drug.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 7.0 year   | Tentative approval is notification that an NDA or ANDA otherwise meets the requirements for approval under the Federal Food, Drug, and Cosmetic Act, but cannot be approved because there is a 7-year period of orphan exclusivity for a listed drug under section 527 of the Federal Food, Drug, and Cosmetic Act and &#167;&#8201;316.31 of this chapter, or that a 505(b)(2) application or ANDA otherwise meets the requirements for approval under the Federal Food, Drug, and Cosmetic Act, but cannot be approved until the conditions in &#167;&#8201;314.107(b)(1)(iii), (b)(3), or (c) are met; because there is a period of exclusivity for the listed drug under &#167;&#8201;314.108; because there is a period of pediatric exclusivity for the listed drug under section 505A of the Federal Food, Drug, and Cosmetic Act; because there is a period of exclusivity for the listed drug under section 505E of the Federal Food, Drug, and Cosmetic Act; or because a court order pursuant to 35 U.S.C. 271(e)(4)(A) orders that the NDA or ANDA may be approved no earlier than the date specified.                                        |
| 120.0 day  | (iv) The applicant may, at its option, submit a complete chemistry, manufacturing, and controls section 90 to 120 days before the anticipated submission of the remainder of the NDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 4.0 month  | The applicant must submit these reports (1) 4 months after the initial submission; (2) in a resubmission following receipt of a complete response letter; and (3) at other times as requested by FDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 30.0 day   | The applicant's failure to submit information requested by FDA within 30 days after receipt of the request may result in the agency viewing any eventual submission as a major amendment under &#167;&#8201;314.60 and extending the review period as necessary.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 30.0 day   | (i) If a patent described in paragraph (i)(1)(i)(A) of this section is issued and the holder of the approved NDA for the patented drug does not file with FDA the required information on the patent within 30 days of issuance of the patent, an applicant who submitted a 505(b)(2) application that, before the submission of the patent information, contained an appropriate patent certification or statement is not required to submit a patent certification or statement to address the patent or patent information that is late-listed with respect to the pending 505(b)(2) application.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 30.0 day   | Except as provided in &#167;&#8201;314.53(f)(1), an NDA holder's amendment to the description of the approved method(s) of use claimed by the patent will be considered untimely filing of patent information unless:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (A) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of patent issuance;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (B) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of approval of a corresponding change to product labeling; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (C) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of a decision by the U.S. Patent and Trademark Office or by a Federal district court, the Court of Appeals for the Federal Circuit, or the U.S. Supreme Court that is specific to the patent and alters the construction of a method-of-use claim(s) of the patent, and the amendment contains a copy of the decision.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 30.0 day   | Except as provided in &#167;&#8201;314.53(f)(1), an NDA holder's amendment to the description of the approved method(s) of use claimed by the patent will be considered untimely filing of patent information unless:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (A) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of patent issuance;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (B) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of approval of a corresponding change to product labeling; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (C) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of a decision by the U.S. Patent and Trademark Office or by a Federal district court, the Court of Appeals for the Federal Circuit, or the U.S. Supreme Court that is specific to the patent and alters the construction of a method-of-use claim(s) of the patent, and the amendment contains a copy of the decision.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 30.0 day   | Except as provided in &#167;&#8201;314.53(f)(1), an NDA holder's amendment to the description of the approved method(s) of use claimed by the patent will be considered untimely filing of patent information unless:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (A) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of patent issuance;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (B) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of approval of a corresponding change to product labeling; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (C) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of a decision by the U.S. Patent and Trademark Office or by a Federal district court, the Court of Appeals for the Federal Circuit, or the U.S. Supreme Court that is specific to the patent and alters the construction of a method-of-use claim(s) of the patent, and the amendment contains a copy of the decision.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 180.0 day  | If the list reflects that an NDA holder has requested that a patent or patent information be removed from the list and no ANDA applicant is eligible for 180-day exclusivity based on a paragraph IV certification to that patent, the patent or patent information will be removed and any applicant with a pending 505(b)(2) application (including a tentatively approved 505(b)(2) application) who has made a certification with respect to such patent must submit an amendment to withdraw its certification.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 180.0 day  | If the list reflects that an NDA holder has requested that a patent or patent information be removed from the list and one or more first applicants are eligible for 180-day exclusivity based on a paragraph IV certification to that patent, the patent will remain listed until any 180-day exclusivity based on that patent has expired or has been extinguished.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 180.0 day  | If the list reflects that an NDA holder has requested that a patent or patent information be removed from the list and one or more first applicants are eligible for 180-day exclusivity based on a paragraph IV certification to that patent, the patent will remain listed until any 180-day exclusivity based on that patent has expired or has been extinguished.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 180.0 day  | A 505(b)(2) applicant is not required to provide or maintain a certification to a patent or patent information that remains listed only for purposes of a first applicant's 180-day exclusivity for its ANDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 20.0 day   | (1) Except as provided under paragraph (d) of this section, the applicant must send the notice required by paragraph (a) of this section on or after the date of filing described in &#167;&#8201;314.101(a)(2) or (3), as applicable, but not later than 20 days after the date of the postmark on the paragraph IV acknowledgment letter.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 20.0 day   | The 20-day clock described in this paragraph (b) begins on the day after the date of the postmark on the paragraph IV acknowledgment letter.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 30.0 day   | The amendment must be submitted to FDA within 30 days after the last date on which notice was received by a person described in paragraph (a) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 45 day     | (f) Forty-five day period after receipt of notice.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 1 day      | If the requirements of this section are met, the Agency will presume the notice to be complete and sufficient and will count the day following the date of receipt of the notice by the patent owner or its representative and by the approved NDA holder or its attorney, agent, or other authorized official as the first day of the 45-day period provided for in section 505(c)(3)(C) of the Federal Food, Drug, and Cosmetic Act.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 45.0 day   | If the requirements of this section are met, the Agency will presume the notice to be complete and sufficient and will count the day following the date of receipt of the notice by the patent owner or its representative and by the approved NDA holder or its attorney, agent, or other authorized official as the first day of the 45-day period provided for in section 505(c)(3)(C) of the Federal Food, Drug, and Cosmetic Act.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 2.0 day    | (1) For purposes of this section, the term &#8220;designated delivery service&#8221; is any delivery service provided by a trade or business that the Agency determines:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (i) Is available to the general public throughout the United States;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (ii) Records electronically to its database, kept in the regular course of its business, or marks on the cover in which any item referred to in this section is to be delivered, the date on which such item was given to such trade or business for delivery; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (iii) Provides overnight or 2-day delivery service throughout the United States.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 30.0 day   | Within 30 days after the date of approval of its NDA or supplement, the applicant must submit Form FDA 3542 for each patent that claims the drug substance (active ingredient), drug product (formulation and composition), or approved method of use.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 30.0 day   | As described in paragraph (d)(3) of this section, to be timely filed, patent information for patents issued after the date of approval of the NDA must be submitted to FDA within 30 days of the date of issuance of the patent.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 30.0 day   | If the applicant submits the required patent information within the 30 days, but we notify an applicant that a declaration form is incomplete or shows that the patent is not eligible for listing, the applicant must submit an acceptable declaration form within 15 days of FDA notification to be considered timely filed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 15.0 day   | If the applicant submits the required patent information within the 30 days, but we notify an applicant that a declaration form is incomplete or shows that the patent is not eligible for listing, the applicant must submit an acceptable declaration form within 15 days of FDA notification to be considered timely filed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 30.0 day   | If a patent is issued after the NDA is filed with FDA but before the NDA is approved, the applicant must, within 30 days of the date of issuance of the patent, submit the required patent information in an amendment to the NDA under &#167;&#8201;314.60.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 30.0 day   | If a patent is issued for a drug substance, drug product, or method of use after an NDA is approved, the applicant must submit to FDA, as described in paragraph (d)(4) of this section, the required patent information within 30 days of the date of issuance of the patent.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 30.0 day   | If the required patent information is not submitted within 30 days of the issuance of the patent, FDA will list the patent, but patent certifications or statements will be governed by the provisions regarding untimely filed patent information at &#167;&#167;&#8201;314.50(i)(4) and (6) and 314.94(a)(12)(vi) and (viii).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 30.0 day   | The NDA holder must confirm the correctness of the patent information and include the signed verification required by paragraph (c)(2)(ii)(R) of this section or withdraw or amend the patent information in accordance with paragraph (f)(2) of this section within 30 days of the date on which the Agency sends the statement of dispute.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 30.0 day   | The NDA holder must confirm the correctness of its description of the approved method of use claimed by the patent that has been included as the &#8220;Use Code&#8221; in the Orange Book, or withdraw or amend the patent information in accordance with paragraph (f)(2) of this section, provide a narrative description (no more than 250 words) of the NDA holder's interpretation of the scope of the patent that explains why the existing or amended &#8220;Use Code&#8221; describes only the specific approved method of use claimed by the patent for which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug product, and include the signed verification required by paragraph (c)(2)(ii)(R) of this section within 30 days of the date on which the Agency sends the statement of dispute.                                                                                                                                                                                                                              |
| 30.0 day   | (1) If the NDA holder confirms the correctness of the patent information, provides the narrative description required by paragraph (f)(1)(i)(B) of this section, and includes the signed verification required by paragraph (c)(2)(ii)(R) of this section within 30 days of the date on which the Agency sends the statement of dispute, the Agency will not change the patent information in the Orange Book.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 30.0 day   | (2) If the NDA holder responds to the patent listing dispute with amended patent information in accordance with paragraph (f)(2) of this section, provides the narrative description required by paragraph (f)(1)(i)(B) of this section, and includes the signed verification required by paragraph (c)(2)(ii)(R) of this section within 30 days of the date on which the Agency sends the statement of dispute, FDA will update the Orange Book to reflect the amended patent information.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 14.0 day   | If the NDA holder is required by court order to amend patent information or withdraw a patent from the list, it must submit an amendment to its NDA that includes a copy of the order, within 14 days of the date the order was entered, to the Central Document Room, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 180.0 day  | FDA will remove a patent or patent information from the list if there is no first applicant eligible for 180-day exclusivity based on a paragraph IV certification to that patent or after the 180-day exclusivity period of a first applicant based on that patent has expired or has been extinguished.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 180.0 day  | FDA will remove a patent or patent information from the list if there is no first applicant eligible for 180-day exclusivity based on a paragraph IV certification to that patent or after the 180-day exclusivity period of a first applicant based on that patent has expired or has been extinguished.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 30.0 day   | This correction must be submitted within 30 days of receipt of a certificate of extension as described in 35 U.S.C. 156(e)(1) or documentation of an extension of the term of the patent as described in 35 U.S.C. 156(e)(2).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 3.0 month  | (1) Submission of a major amendment to an original NDA, efficacy supplement, or resubmission of an NDA or efficacy supplement within 3 months of the end of the initial review cycle constitutes an agreement by the applicant under section 505(c) of the Federal Food, Drug, and Cosmetic Act to extend the initial review cycle by 3 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 3.0 month  | (1) Submission of a major amendment to an original NDA, efficacy supplement, or resubmission of an NDA or efficacy supplement within 3 months of the end of the initial review cycle constitutes an agreement by the applicant under section 505(c) of the Federal Food, Drug, and Cosmetic Act to extend the initial review cycle by 3 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 3.0 month  | (2) Submission of a major amendment to an original NDA, efficacy supplement, or resubmission of an NDA or efficacy supplement more than 3 months before the end of the initial review cycle will not extend the cycle.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 2.0 month  | (4) Submission of a major amendment to a manufacturing supplement within 2 months of the end of the initial review cycle constitutes an agreement by the applicant under section 505(c) of the Federal Food, Drug, and Cosmetic Act to extend the initial review cycle by 2 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 2.0 month  | (4) Submission of a major amendment to a manufacturing supplement within 2 months of the end of the initial review cycle constitutes an agreement by the applicant under section 505(c) of the Federal Food, Drug, and Cosmetic Act to extend the initial review cycle by 2 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 30.0 day   | Such a supplement should be plainly marked: &#8220;Prior Approval Supplement-Expedited Review Requested.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (c) Changes requiring supplement submission at least 30 days prior to distribution of the drug product made using the change (moderate changes).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 30.0 day   | The supplement must be labeled &#8220;Supplement&#8212;Changes Being Effected in 30 Days&#8221; or, if applicable under paragraph (c)(6) of this section, &#8220;Supplement&#8212;Changes Being Effected.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (4) Pending approval of the supplement by FDA, except as provided in paragraph (c)(6) of this section, distribution of the drug product made using the change may begin not less than 30 days after receipt of the supplement by FDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 30.0 day   | The supplement must be labeled &#8220;Supplement&#8212;Changes Being Effected in 30 Days&#8221; or, if applicable under paragraph (c)(6) of this section, &#8220;Supplement&#8212;Changes Being Effected.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (4) Pending approval of the supplement by FDA, except as provided in paragraph (c)(6) of this section, distribution of the drug product made using the change may begin not less than 30 days after receipt of the supplement by FDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 30.0 day   | (5) The applicant must not distribute the drug product made using the change if within 30 days following FDA's receipt of the supplement, FDA informs the applicant that either:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (i) The change requires approval prior to distribution of the drug product in accordance with paragraph (b) of this section; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (ii) Any of the information required under paragraph (c)(4) of this section is missing; the applicant must not distribute the drug product made using the change until the supplement has been amended to provide the missing information.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 15.0 day   | (1)(i) Postmarketing 15-day &#8220;Alert reports&#8221;.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 15.0 day   | The applicant must report each adverse drug experience that is both serious and unexpected, whether foreign or domestic, as soon as possible but no later than 15 calendar days from initial receipt of the information by the applicant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 15.0 day   | (ii) Postmarketing 15-day &#8220;Alert reports&#8221;&#8212;followup.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 15.0 day   | The applicant must promptly investigate all adverse drug experiences that are the subject of these postmarketing 15-day Alert reports and must submit followup reports within 15 calendar days of receipt of new information or as requested by FDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 15.0 day   | The applicant must promptly investigate all adverse drug experiences that are the subject of these postmarketing 15-day Alert reports and must submit followup reports within 15 calendar days of receipt of new information or as requested by FDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 15.0 day   | The requirements of paragraphs (c)(1)(i) and (c)(1)(ii) of this section, concerning the submission of postmarketing 15-day Alert reports, also apply to any person other than the applicant whose name appears on the label of an approved drug product as a manufacturer, packer, or distributor (nonapplicant).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 5.0 day    | If a nonapplicant elects to submit adverse drug experience reports to the applicant rather than to FDA, the nonapplicant must submit, by any appropriate means, each report to the applicant within 5 calendar days of initial receipt of the information by the nonapplicant, and the applicant must then comply with the requirements of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 3.0 year   | (i) The applicant must report each adverse drug experience not reported under paragraph (c)(1)(i) of this section at quarterly intervals, for 3 years from the date of approval of the application, and then at annual intervals.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 30.0 day   | The applicant must submit each quarterly report within 30 days of the close of the quarter (the first quarter beginning on the date of approval of the application) and each annual report within 60 days of the anniversary date of approval of the application.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 1 quarter  | The applicant must submit each quarterly report within 30 days of the close of the quarter (the first quarter beginning on the date of approval of the application) and each annual report within 60 days of the anniversary date of approval of the application.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 60.0 day   | The applicant must submit each quarterly report within 30 days of the close of the quarter (the first quarter beginning on the date of approval of the application) and each annual report within 60 days of the anniversary date of approval of the application.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 15.0 day   | (1) A narrative summary and analysis of the information in the report;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|            |               (2) An analysis of the 15-day Alert reports submitted during the reporting interval (all 15-day Alert reports being appropriately referenced by the applicant's patient identification code, adverse reaction term(s), and date of submission to FDA);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (3) A history of actions taken since the last report because of adverse drug experiences (for example, labeling changes or studies initiated); and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (4) An index consisting of a line listing of the applicant's patient identification code, and adverse reaction term(s) for all ICSRs submitted under paragraph (c)(2)(ii)(B) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 15.0 day   | (1) A narrative summary and analysis of the information in the report;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|            |               (2) An analysis of the 15-day Alert reports submitted during the reporting interval (all 15-day Alert reports being appropriately referenced by the applicant's patient identification code, adverse reaction term(s), and date of submission to FDA);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (3) A history of actions taken since the last report because of adverse drug experiences (for example, labeling changes or studies initiated); and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (4) An index consisting of a line listing of the applicant's patient identification code, and adverse reaction term(s) for all ICSRs submitted under paragraph (c)(2)(ii)(B) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 15.0 day   | (iii) Periodic reporting, except for information regarding 15-day Alert reports, does not apply to adverse drug experience information obtained from postmarketing studies (whether or not conducted under an investigational new drug application), from reports in the scientific literature, and from foreign marketing experience.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 15.0 day   | A 15-day Alert report based on information in the scientific literature must be accompanied by a copy of the published article.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 15.0 day   | The 15-day reporting requirements in paragraph (c)(1)(i) of this section (i.e., serious, unexpected adverse drug experiences) apply only to reports found in scientific and medical journals either as case reports or as the result of a formal clinical trial.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 15.0 day   | An applicant is not required to submit a 15-day Alert report under paragraph (c) of this section for an adverse drug experience obtained from a postmarketing study (whether or not conducted under an investigational new drug application) unless the applicant concludes that there is a reasonable possibility that the drug caused the adverse experience.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 15.0 day   | (i) Applicant name and contact office address;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (ii) Telephone number;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (iii) Report source, such as spontaneous, literature, or study;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (iv) Date the report was received by applicant;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (v) Application number and type;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (vi) Whether the ICSR is a 15-day &#8220;Alert report&#8221;;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (vii) Whether the ICSR is an initial report or followup report; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (viii) Unique case identification number, which must be the same in the initial report and any subsequent followup report(s).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.0 year  | The applicant must maintain for a period of 10 years records of all adverse drug experiences known to the applicant, including raw data and any correspondence relating to adverse drug experiences.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 60.0 day   | The applicant shall submit each year within 60 days of the anniversary date of U.S. approval of the application, two copies of the report to the FDA division responsible for reviewing the application.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1.0 year   | (A study is considered completed 1 year after it is concluded.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 6.0 month  | (b) Notifications required by paragraph (b)(3)(iii)(a) of this section must be submitted to FDA electronically in a format that FDA can process, review, and archive:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (1) At least 6 months prior to the date of the permanent discontinuance or interruption in manufacturing; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (2) If 6 months' advance notice is not possible because the permanent discontinuance or interruption in manufacturing was not reasonably anticipated 6 months in advance, as soon as practicable thereafter, but in no case later than 5 business days after the permanent discontinuance or interruption in manufacturing occurs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 6.0 month  | (b) Notifications required by paragraph (b)(3)(iii)(a) of this section must be submitted to FDA electronically in a format that FDA can process, review, and archive:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (1) At least 6 months prior to the date of the permanent discontinuance or interruption in manufacturing; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (2) If 6 months' advance notice is not possible because the permanent discontinuance or interruption in manufacturing was not reasonably anticipated 6 months in advance, as soon as practicable thereafter, but in no case later than 5 business days after the permanent discontinuance or interruption in manufacturing occurs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 6.0 month  | (b) Notifications required by paragraph (b)(3)(iii)(a) of this section must be submitted to FDA electronically in a format that FDA can process, review, and archive:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (1) At least 6 months prior to the date of the permanent discontinuance or interruption in manufacturing; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (2) If 6 months' advance notice is not possible because the permanent discontinuance or interruption in manufacturing was not reasonably anticipated 6 months in advance, as soon as practicable thereafter, but in no case later than 5 business days after the permanent discontinuance or interruption in manufacturing occurs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 5.0 day    | (b) Notifications required by paragraph (b)(3)(iii)(a) of this section must be submitted to FDA electronically in a format that FDA can process, review, and archive:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (1) At least 6 months prior to the date of the permanent discontinuance or interruption in manufacturing; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (2) If 6 months' advance notice is not possible because the permanent discontinuance or interruption in manufacturing was not reasonably anticipated 6 months in advance, as soon as practicable thereafter, but in no case later than 5 business days after the permanent discontinuance or interruption in manufacturing occurs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 30.0 day   | (1) Not later than 30 calendar days after the issuance of such a letter, the applicant must submit to FDA a written response setting forth the basis for noncompliance and providing the required notification under paragraph (b)(3)(iii)(a) of this section and including the information required under paragraph (b)(3)(iii)(c) of this section; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (2) Not later than 45 calendar days after the issuance of a letter under paragraph (b)(3)(iii)(e) of this section, FDA will make the letter and the applicant's response to the letter public, unless, after review of the applicant's response, FDA determines that the applicant had a reasonable basis for not notifying FDA as required under paragraph (b)(3)(iii)(a) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 45.0 day   | (1) Not later than 30 calendar days after the issuance of such a letter, the applicant must submit to FDA a written response setting forth the basis for noncompliance and providing the required notification under paragraph (b)(3)(iii)(a) of this section and including the information required under paragraph (b)(3)(iii)(c) of this section; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (2) Not later than 45 calendar days after the issuance of a letter under paragraph (b)(3)(iii)(e) of this section, FDA will make the letter and the applicant's response to the letter public, unless, after review of the applicant's response, FDA determines that the applicant had a reasonable basis for not notifying FDA as required under paragraph (b)(3)(iii)(a) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 30.0 day   | (a) Within 30 calendar days of the withdrawal of an approved drug from sale, applicants who are manufacturers, repackers, or relabelers subject to part 207 of this chapter must submit the following information about the drug, in accordance with the applicable requirements described in &#167;&#167;&#8201;207.61 and 207.65:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (1) The National Drug Code (NDC);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (2) The identity of the drug by established name and by proprietary name, if any;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (3) The new drug application number or abbreviated application number;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (4) The date on which the drug is expected to be no longer in commercial distribution.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 30.0 day   | (b) Within 30 calendar days of the withdrawal of an approved drug from sale, applicants who are not subject to part 207 of this chapter must submit the information listed in paragraphs (b)(3)(iv)(a)(1) through (4) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 90.0 day   | (e) No later than 90 days after the date a petition that is permitted under paragraph (a) of this section is submitted, FDA will approve or disapprove the petition.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 30.0 day   | (A) If a patent on the listed drug is issued and the holder of the approved NDA for the listed drug does not file with FDA the required information on the patent within 30 days of issuance of the patent, an applicant who submitted an ANDA for that drug that contained an appropriate patent certification or statement before the submission of the patent information is not required to submit a patent certification or statement to address the patent or patent information that is late-listed with respect to the pending ANDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 30.0 day   | (1) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of patent issuance;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (2) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of approval of a corresponding change to product labeling; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (3) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of a decision by the U.S. Patent and Trademark Office or by a Federal district court, the Court of Appeals for the Federal Circuit, or the U.S. Supreme Court that is specific to the patent and alters the construction of a method-of-use claim(s) of the patent, and the amendment contains a copy of the decision.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 30.0 day   | (1) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of patent issuance;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (2) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of approval of a corresponding change to product labeling; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (3) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of a decision by the U.S. Patent and Trademark Office or by a Federal district court, the Court of Appeals for the Federal Circuit, or the U.S. Supreme Court that is specific to the patent and alters the construction of a method-of-use claim(s) of the patent, and the amendment contains a copy of the decision.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 30.0 day   | (1) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of patent issuance;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (2) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of approval of a corresponding change to product labeling; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (3) The amendment to the description of the approved method(s) of use claimed by the patent is submitted within 30 days of a decision by the U.S. Patent and Trademark Office or by a Federal district court, the Court of Appeals for the Federal Circuit, or the U.S. Supreme Court that is specific to the patent and alters the construction of a method-of-use claim(s) of the patent, and the amendment contains a copy of the decision.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 180.0 day  | If the list reflects that an NDA holder has requested that a patent or patent information be removed from the list and no ANDA applicant is eligible for 180-day exclusivity based on a paragraph IV certification to that patent, the patent or patent information will be removed and any applicant with a pending ANDA (including a tentatively approved ANDA) who has made a certification with respect to such patent must submit an amendment to withdraw its certification.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 180.0 day  | If the list reflects that an NDA holder has requested that a patent or patent information be removed from the list and one or more first applicants are eligible for 180-day exclusivity based on a paragraph IV certification to that patent, the patent will remain listed until any 180-day exclusivity based on that patent has expired or has been extinguished.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 180.0 day  | If the list reflects that an NDA holder has requested that a patent or patent information be removed from the list and one or more first applicants are eligible for 180-day exclusivity based on a paragraph IV certification to that patent, the patent will remain listed until any 180-day exclusivity based on that patent has expired or has been extinguished.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 180.0 day  | After any applicable 180-day exclusivity has expired or has been extinguished, the patent or patent information will be removed and any applicant with a pending ANDA (including a tentatively approved ANDA) who has made a certification with respect to such patent must submit an amendment to withdraw its certification.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 20.0 day   | (1) Except as provided under paragraph (d) of this section, the applicant must send the notice required by paragraph (a) of this section on or after the date it receives a paragraph IV acknowledgment letter from FDA, but not later than 20 days after the date of the postmark on the paragraph IV acknowledgment letter.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 20.0 day   | The 20-day clock described in this paragraph (b) begins on the day after the date of the postmark on the paragraph IV acknowledgment letter.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 30.0 day   | The amendment must be submitted to FDA within 30 days after the last date on which notice was received by a person described in paragraph (a) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 45 day     | (f) Forty-five day period after receipt of notice.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 1 day      | If the requirements of this section are met, FDA will presume the notice to be complete and sufficient, and it will count the day following the date of receipt of the notice by the patent owner or its representative and by the approved NDA holder or its attorney, agent, or other authorized official as the first day of the 45-day period provided for in section 505(j)(5)(B)(iii) of the Federal Food, Drug, and Cosmetic Act.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 45.0 day   | If the requirements of this section are met, FDA will presume the notice to be complete and sufficient, and it will count the day following the date of receipt of the notice by the patent owner or its representative and by the approved NDA holder or its attorney, agent, or other authorized official as the first day of the 45-day period provided for in section 505(j)(5)(B)(iii) of the Federal Food, Drug, and Cosmetic Act.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 2.0 day    | (1) For purposes of this section, the term &#8220;designated delivery service&#8221; means any delivery service provided by a trade or business that the Agency determines:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (i) Is available to the general public throughout the United States;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (ii) Records electronically to its database, kept in the regular course of its business, or marks on the cover in which any item referred to in this section is to be delivered, the date on which such item was given to such trade or business for delivery; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (iii) Provides overnight or 2-day delivery service throughout the United States.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 180.0 day  | (2) Submission of an amendment containing significant data or information before the end of the initial review cycle constitutes an agreement between FDA and the applicant to extend the initial review cycle only for the time necessary to review the significant data or information and for no more than 180 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 180.0 day  | (a) Except as provided in paragraph (c) of this section, within 180 days of receipt of an application for a new drug under section 505(b) of the act or an abbreviated application for a new drug under section 505(j) of the act, FDA will review it and send the applicant either an approval letter under &#167;&#8201;314.105 or a complete response letter under &#167;&#8201;314.110.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 180.0 day  | This 180-day period is called the &#8220;initial review cycle.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (b) At any time before approval, an applicant may withdraw an application under &#167;&#8201;314.65 or an abbreviated application under &#167;&#8201;314.99 and later submit it again for consideration.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 60.0 day   | (1) Within 60 days after FDA receives an NDA, the Agency will determine whether the NDA may be filed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 60.0 day   | The date of filing will be the date 60 days after the date FDA received the NDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 180.0 day  | The date of filing begins the 180-day period described in section 505(c) of the Federal Food, Drug, and Cosmetic Act.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 180.0 day  | This 180-day period is called the &#8220;filing clock.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (3) If FDA refuses to file the NDA, the Agency will notify the applicant in writing and state the reason under paragraph (d) or (e) of this section for the refusal.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 30.0 day   | If FDA refuses to file the NDA under paragraph (d) of this section, the applicant may request in writing within 30 days of the date of the Agency's notification an informal conference with the Agency about whether the Agency should file the NDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 60.0 day   | If the NDA is filed over protest, the date of filing will be the date 60 days after the date the applicant requested the informal conference.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1.0 year   | The applicant may then:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|            |               (i) Withdraw the ANDA under &#167;&#8201;314.99; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (ii) Correct the deficiencies and resubmit the ANDA; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (iii) Take no action, in which case FDA may consider the ANDA withdrawn after 1 year.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 180.0 day  | (1) Within 180 days after the date of filing, plus the period of time the review period was extended (if any), FDA will either:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (i) Approve the NDA; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (ii) Issue a notice of opportunity for a hearing if the applicant asked FDA to provide it an opportunity for a hearing on an NDA in response to a complete response letter.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 180.0 day  | (2) Within 180 days after the date of receipt, plus the period of time the review clock was extended (if any), FDA will either approve or disapprove the ANDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 90 day     | (c) Ninety-day conference.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 90.0 day   | Approximately 90 days after the agency receives the application, FDA will provide applicants with an opportunity to meet with agency reviewing officials.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 90 day     | In addition, the &#8220;ninety-day conference&#8221; described in &#167;&#8201;314.102(c) will provide a timely forum for discussing and resolving, if possible, issues identified by that date.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 7.0 year   | FDA will issue a tentative approval letter if an NDA otherwise meets the requirements for approval under the Federal Food, Drug, and Cosmetic Act, but cannot be approved because there is a 7-year period of orphan exclusivity for the listed drug under section 527 of the Federal Food, Drug, and Cosmetic Act and &#167;&#8201;316.31 of this chapter, or if a 505(b)(2) application otherwise meets the requirements for approval under the Federal Food, Drug, and Cosmetic Act, but cannot be approved until the conditions in &#167;&#8201;314.107(b)(3) are met; because there is a period of exclusivity for the listed drug under &#167;&#8201;314.108; because there is a period of pediatric exclusivity for the listed drug under section 505A of the Federal Food, Drug, and Cosmetic Act; or because there is a period of exclusivity for the listed drug under section 505E of the Federal Food, Drug, and Cosmetic Act.                                                                                                                                                                                                                |
| 7.0 year   | FDA will issue a tentative approval letter if an ANDA otherwise meets the requirements for approval under the Federal Food, Drug, and Cosmetic Act, but cannot be approved because there is a 7-year period of orphan exclusivity for the listed drug under section 527 of the Federal Food, Drug, and Cosmetic Act and &#167;&#8201;316.31 of this chapter, or cannot be approved until the conditions in &#167;&#8201;314.107(b)(3) or (c) are met; because there is a period of exclusivity for the listed drug under &#167;&#8201;314.108; because there is a period of pediatric exclusivity for the listed drug under section 505A of the Federal Food, Drug, and Cosmetic Act; or because there is a period of exclusivity for the listed drug under section 505E of the Federal Food, Drug, and Cosmetic Act.                                                                                                                                                                                                                                                                                                                                     |
| 45.0 day   | If none of the reasons in &#167;&#8201;314.125 or &#167;&#8201;314.127, as applicable, for refusing to approve the 505(b)(2) application or ANDA applies, and none of the reasons in paragraph (d) of this section for delaying approval applies, the 505(b)(2) application or ANDA may be approved as follows:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (i) Immediately, if the applicant certifies under &#167;&#8201;314.50(i) or &#167;&#8201;314.94(a)(12) that:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (A) The applicant is aware of a relevant patent but the patent information required under section 505(b) or (c) of the Federal Food, Drug, and Cosmetic Act has not been submitted to FDA; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (B) The relevant patent has expired; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (C) The relevant patent is invalid, unenforceable, or will not be infringed, except as provided in paragraphs (b)(3) and (c) of this section, and the 45-day period provided for in section 505(c)(3)(C) and (j)(5)(B)(iii) of the Federal Food, Drug, and Cosmetic Act has expired; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (D) There are no relevant patents.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 45.0 day   | The 45-day period provided for in section 505(c)(3)(C) and (j)(5)(B)(iii) of the Federal Food, Drug, and Cosmetic Act does not apply in these circumstances.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 30.0 month | (3) Disposition of patent litigation&#8212;(i) Approval upon expiration of 30-month period or 71/2 years from date of listed drug approval.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 45.0 day   | (A) Except as provided in paragraphs (b)(3)(ii) through (viii) of this section, if, with respect to patents for which required information was submitted under &#167;&#8201;314.53 before the date on which the 505(b)(2) application or ANDA was submitted to FDA (excluding an amendment or supplement to the 505(b)(2) application or ANDA), the applicant certifies under &#167;&#8201;314.50(i) or &#167;&#8201;314.94(a)(12) that the relevant patent is invalid, unenforceable, or will not be infringed, and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement within 45 days of receipt of the notice of certification from the applicant under &#167;&#8201;314.52 or &#167;&#8201;314.95, the 505(b)(2) application or ANDA may be approved 30 months after the later of the date of the receipt of the notice of certification by any owner of the listed patent or by the NDA holder (or its representative(s)) unless the court has extended or reduced the period because of a failure of either the plaintiff or defendant to cooperate reasonably in expediting the action; or |
|            |               (B) If the patented drug product qualifies for 5 years of exclusive marketing under &#167;&#8201;314.108(b)(2) and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement during the 1-year period beginning 4 years after the date of approval of the patented drug and within 45 days of receipt of the notice of certification from the applicant under &#167;&#8201;314.52 or &#167;&#8201;314.95, the 505(b)(2) application or ANDA may be approved at the expiration of the 71/2 years from the date of approval of the NDA for the patented drug product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 30.0 month | (A) Except as provided in paragraphs (b)(3)(ii) through (viii) of this section, if, with respect to patents for which required information was submitted under &#167;&#8201;314.53 before the date on which the 505(b)(2) application or ANDA was submitted to FDA (excluding an amendment or supplement to the 505(b)(2) application or ANDA), the applicant certifies under &#167;&#8201;314.50(i) or &#167;&#8201;314.94(a)(12) that the relevant patent is invalid, unenforceable, or will not be infringed, and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement within 45 days of receipt of the notice of certification from the applicant under &#167;&#8201;314.52 or &#167;&#8201;314.95, the 505(b)(2) application or ANDA may be approved 30 months after the later of the date of the receipt of the notice of certification by any owner of the listed patent or by the NDA holder (or its representative(s)) unless the court has extended or reduced the period because of a failure of either the plaintiff or defendant to cooperate reasonably in expediting the action; or |
|            |               (B) If the patented drug product qualifies for 5 years of exclusive marketing under &#167;&#8201;314.108(b)(2) and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement during the 1-year period beginning 4 years after the date of approval of the patented drug and within 45 days of receipt of the notice of certification from the applicant under &#167;&#8201;314.52 or &#167;&#8201;314.95, the 505(b)(2) application or ANDA may be approved at the expiration of the 71/2 years from the date of approval of the NDA for the patented drug product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 5.0 year   | (A) Except as provided in paragraphs (b)(3)(ii) through (viii) of this section, if, with respect to patents for which required information was submitted under &#167;&#8201;314.53 before the date on which the 505(b)(2) application or ANDA was submitted to FDA (excluding an amendment or supplement to the 505(b)(2) application or ANDA), the applicant certifies under &#167;&#8201;314.50(i) or &#167;&#8201;314.94(a)(12) that the relevant patent is invalid, unenforceable, or will not be infringed, and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement within 45 days of receipt of the notice of certification from the applicant under &#167;&#8201;314.52 or &#167;&#8201;314.95, the 505(b)(2) application or ANDA may be approved 30 months after the later of the date of the receipt of the notice of certification by any owner of the listed patent or by the NDA holder (or its representative(s)) unless the court has extended or reduced the period because of a failure of either the plaintiff or defendant to cooperate reasonably in expediting the action; or |
|            |               (B) If the patented drug product qualifies for 5 years of exclusive marketing under &#167;&#8201;314.108(b)(2) and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement during the 1-year period beginning 4 years after the date of approval of the patented drug and within 45 days of receipt of the notice of certification from the applicant under &#167;&#8201;314.52 or &#167;&#8201;314.95, the 505(b)(2) application or ANDA may be approved at the expiration of the 71/2 years from the date of approval of the NDA for the patented drug product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1.0 year   | (A) Except as provided in paragraphs (b)(3)(ii) through (viii) of this section, if, with respect to patents for which required information was submitted under &#167;&#8201;314.53 before the date on which the 505(b)(2) application or ANDA was submitted to FDA (excluding an amendment or supplement to the 505(b)(2) application or ANDA), the applicant certifies under &#167;&#8201;314.50(i) or &#167;&#8201;314.94(a)(12) that the relevant patent is invalid, unenforceable, or will not be infringed, and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement within 45 days of receipt of the notice of certification from the applicant under &#167;&#8201;314.52 or &#167;&#8201;314.95, the 505(b)(2) application or ANDA may be approved 30 months after the later of the date of the receipt of the notice of certification by any owner of the listed patent or by the NDA holder (or its representative(s)) unless the court has extended or reduced the period because of a failure of either the plaintiff or defendant to cooperate reasonably in expediting the action; or |
|            |               (B) If the patented drug product qualifies for 5 years of exclusive marketing under &#167;&#8201;314.108(b)(2) and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement during the 1-year period beginning 4 years after the date of approval of the patented drug and within 45 days of receipt of the notice of certification from the applicant under &#167;&#8201;314.52 or &#167;&#8201;314.95, the 505(b)(2) application or ANDA may be approved at the expiration of the 71/2 years from the date of approval of the NDA for the patented drug product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 4.0 year   | (A) Except as provided in paragraphs (b)(3)(ii) through (viii) of this section, if, with respect to patents for which required information was submitted under &#167;&#8201;314.53 before the date on which the 505(b)(2) application or ANDA was submitted to FDA (excluding an amendment or supplement to the 505(b)(2) application or ANDA), the applicant certifies under &#167;&#8201;314.50(i) or &#167;&#8201;314.94(a)(12) that the relevant patent is invalid, unenforceable, or will not be infringed, and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement within 45 days of receipt of the notice of certification from the applicant under &#167;&#8201;314.52 or &#167;&#8201;314.95, the 505(b)(2) application or ANDA may be approved 30 months after the later of the date of the receipt of the notice of certification by any owner of the listed patent or by the NDA holder (or its representative(s)) unless the court has extended or reduced the period because of a failure of either the plaintiff or defendant to cooperate reasonably in expediting the action; or |
|            |               (B) If the patented drug product qualifies for 5 years of exclusive marketing under &#167;&#8201;314.108(b)(2) and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement during the 1-year period beginning 4 years after the date of approval of the patented drug and within 45 days of receipt of the notice of certification from the applicant under &#167;&#8201;314.52 or &#167;&#8201;314.95, the 505(b)(2) application or ANDA may be approved at the expiration of the 71/2 years from the date of approval of the NDA for the patented drug product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 45.0 day   | (A) Except as provided in paragraphs (b)(3)(ii) through (viii) of this section, if, with respect to patents for which required information was submitted under &#167;&#8201;314.53 before the date on which the 505(b)(2) application or ANDA was submitted to FDA (excluding an amendment or supplement to the 505(b)(2) application or ANDA), the applicant certifies under &#167;&#8201;314.50(i) or &#167;&#8201;314.94(a)(12) that the relevant patent is invalid, unenforceable, or will not be infringed, and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement within 45 days of receipt of the notice of certification from the applicant under &#167;&#8201;314.52 or &#167;&#8201;314.95, the 505(b)(2) application or ANDA may be approved 30 months after the later of the date of the receipt of the notice of certification by any owner of the listed patent or by the NDA holder (or its representative(s)) unless the court has extended or reduced the period because of a failure of either the plaintiff or defendant to cooperate reasonably in expediting the action; or |
|            |               (B) If the patented drug product qualifies for 5 years of exclusive marketing under &#167;&#8201;314.108(b)(2) and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement during the 1-year period beginning 4 years after the date of approval of the patented drug and within 45 days of receipt of the notice of certification from the applicant under &#167;&#8201;314.52 or &#167;&#8201;314.95, the 505(b)(2) application or ANDA may be approved at the expiration of the 71/2 years from the date of approval of the NDA for the patented drug product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 30.0 month | If before the expiration of the 30-month period, or 71/2 years where applicable, the district court decides that the patent is invalid, unenforceable, or not infringed (including any substantive determination that there is no cause of action for patent infringement or invalidity), the 505(b)(2) application or ANDA may be approved on:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (A) The date on which the court enters judgment reflecting the decision; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (B) The date of a settlement order or consent decree signed and entered by the court stating that the patent that is the subject of the certification is invalid, unenforceable, or not infringed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 30.0 month | If before the expiration of the 30-month period, or 71/2 years where applicable, the district court decides that the patent has been infringed, and if the judgment of the district court is appealed, the 505(b)(2) application or ANDA may be approved on:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (A) The date on which the mandate is issued by the court of appeals entering judgment that the patent is invalid, unenforceable, or not infringed (including any substantive determination that there is no cause of action for patent infringement or invalidity); or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (B) The date of a settlement order or consent decree signed and entered by the court of appeals stating that the patent that is the subject of the certification is invalid, unenforceable, or not infringed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 30.0 month | If before the expiration of the 30-month period, or 71/2 years where applicable, the district court decides that the patent has been infringed, and if the judgment of the district court is not appealed or is affirmed, the 505(b)(2) application or ANDA may be approved no earlier than the date specified by the district court in an order under 35 U.S.C. 271(e)(4)(A).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 30.0 month | If before the expiration of the 30-month period, or 71/2 years where applicable, the district court grants a preliminary injunction prohibiting the applicant from engaging in the commercial manufacture or sale of the drug product until the court decides the issues of patent validity and infringement, and if the court later decides that:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (A) The patent is invalid, unenforceable, or not infringed, the 505(b)(2) application or ANDA may be approved as provided in paragraph (b)(3)(ii) of this section; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (B) The patent is infringed, the 505(b)(2) application or ANDA may be approved as provided in paragraph (b)(3)(iii) or (iv) of this section, whichever is applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 30.0 month | If before the expiration of the 30-month period, or 71/2 years where applicable, the patent owner or the exclusive patent licensee (or their representatives) agrees in writing that the 505(b)(2) application or ANDA may be approved any time on or after the date of the consent, approval may be granted on or after that date.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 30.0 month | (vii) Court order terminating 30-month or 71/2-year period.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 30.0 month | If before the expiration of the 30-month period, or 71/2 years where applicable, the court enters an order requiring the 30-month or 71/2-year period to be terminated, the 505(b)(2) application or ANDA may be approved in accordance with the court's order.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 30.0 month | If before the expiration of the 30-month period, or 71/2 years where applicable, the court enters an order requiring the 30-month or 71/2-year period to be terminated, the 505(b)(2) application or ANDA may be approved in accordance with the court's order.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 30.0 month | If before the expiration of the 30-month period, or 71/2 years where applicable, the court(s) enter(s) an order of dismissal, with or without prejudice, without a finding of infringement in each pending suit for patent infringement brought within 45 days of receipt of the notice of paragraph IV certification sent by the 505(b)(2) or ANDA applicant, the 505(b)(2) application or ANDA may be approved on or after the date of the order.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 45.0 day   | If before the expiration of the 30-month period, or 71/2 years where applicable, the court(s) enter(s) an order of dismissal, with or without prejudice, without a finding of infringement in each pending suit for patent infringement brought within 45 days of receipt of the notice of paragraph IV certification sent by the 505(b)(2) or ANDA applicant, the 505(b)(2) application or ANDA may be approved on or after the date of the order.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 180.0 day  | The ANDA of a subsequent applicant will not be approved during the period when any first applicant is eligible for 180-day exclusivity or during the 180-day exclusivity period of a first applicant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 180.0 day  | The ANDA of a subsequent applicant will not be approved during the period when any first applicant is eligible for 180-day exclusivity or during the 180-day exclusivity period of a first applicant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 180.0 day  | Any applicable 180-day exclusivity period cannot extend beyond the expiration of the patent upon which the 180-day exclusivity period was based.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 180.0 day  | Any applicable 180-day exclusivity period cannot extend beyond the expiration of the patent upon which the 180-day exclusivity period was based.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 30.0 day   | (2) A first applicant must submit correspondence to its ANDA notifying FDA within 30 days of the date of its first commercial marketing of its drug product or the reference listed drug.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 30.0 month | (1) The applicant must submit the following information to FDA, as applicable:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (i) A copy of any judgment by the court (district court or mandate of the court of appeals) or settlement order or consent decree signed and entered by the court (district court or court of appeals) finding a patent described in paragraph (b)(3) of this section invalid, unenforceable, or not infringed, or finding the patent valid and infringed;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (ii) Written notification of whether or not any action by the court described in paragraph (e)(1)(i) of this section has been appealed within the time permitted for an appeal;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (iii) A copy of any order entered by the court terminating the 30-month or 71/2-year period as described in paragraph (b)(3)(i), (ii), (vii), or (viii) of this section;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|            |               (iv) A copy of any written consent to approval by the patent owner or exclusive patent licensee described in paragraph (b)(3)(vi) of this section;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (v) A copy of any preliminary injunction described in paragraph (b)(3)(v) of this section, and a copy of any subsequent court order lifting the injunction; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (vi) A copy of any court order pursuant to 35 U.S.C. 271(e)(4)(A) ordering that a 505(b)(2) application or ANDA may be approved no earlier than the date specified (irrespective of whether the injunction relates to a patent described in paragraph (b)(3) of this section).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 14.0 day   | (2) All information required by paragraph (e)(1) of this section must be sent to the applicant's NDA or ANDA, as appropriate, within 14 days of the date of entry by the court, the date of appeal or expiration of the time for appeal, or the date of written consent to approval, as applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 45 day     | (f) Forty-five day period after receipt of notice of paragraph IV certification&#8212;(1) Computation of 45-day time clock.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 45.0 day   | (f) Forty-five day period after receipt of notice of paragraph IV certification&#8212;(1) Computation of 45-day time clock.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 45.0 day   | The 45-day clock described in paragraph (b)(3) of this section as to each recipient required to receive notice of paragraph IV certification under &#167;&#8201;314.52 or &#167;&#8201;314.95 begins on the day after the date of receipt of the applicant's notice of paragraph IV certification by the recipient.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 14.0 day   | (i) The 505(b)(2) or ANDA applicant must notify FDA in writing within 14 days of the filing of any legal action filed within 45 days of receipt of the notice of paragraph IV certification by any recipient.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 45.0 day   | (i) The 505(b)(2) or ANDA applicant must notify FDA in writing within 14 days of the filing of any legal action filed within 45 days of receipt of the notice of paragraph IV certification by any recipient.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 45.0 day   | (iii) If the 505(b)(2) or ANDA applicant, the patent owner(s), the NDA holder, or its representative(s) does not notify FDA in writing before the expiration of the 45-day time period or the completion of the Agency's review of the 505(b)(2) application or ANDA, whichever occurs later, that a legal action for patent infringement was filed within 45 days of receipt of the notice of paragraph IV certification, the 505(b)(2) application or ANDA may be approved upon expiration of the 45-day period (if the 505(b)(2) or ANDA applicant confirms that a legal action for patent infringement has not been filed) or upon completion of the Agency's review of the 505(b)(2) application or ANDA, whichever is later.                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 45.0 day   | (iii) If the 505(b)(2) or ANDA applicant, the patent owner(s), the NDA holder, or its representative(s) does not notify FDA in writing before the expiration of the 45-day time period or the completion of the Agency's review of the 505(b)(2) application or ANDA, whichever occurs later, that a legal action for patent infringement was filed within 45 days of receipt of the notice of paragraph IV certification, the 505(b)(2) application or ANDA may be approved upon expiration of the 45-day period (if the 505(b)(2) or ANDA applicant confirms that a legal action for patent infringement has not been filed) or upon completion of the Agency's review of the 505(b)(2) application or ANDA, whichever is later.                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 45.0 day   | (iii) If the 505(b)(2) or ANDA applicant, the patent owner(s), the NDA holder, or its representative(s) does not notify FDA in writing before the expiration of the 45-day time period or the completion of the Agency's review of the 505(b)(2) application or ANDA, whichever occurs later, that a legal action for patent infringement was filed within 45 days of receipt of the notice of paragraph IV certification, the 505(b)(2) application or ANDA may be approved upon expiration of the 45-day period (if the 505(b)(2) or ANDA applicant confirms that a legal action for patent infringement has not been filed) or upon completion of the Agency's review of the 505(b)(2) application or ANDA, whichever is later.                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 45.0 day   | If the patent owner or NDA holder who is an exclusive patent licensee (or its representative(s)) waives its opportunity to file a legal action for patent infringement within 45 days of a receipt of the notice of certification and the patent owner or NDA holder who is an exclusive patent licensee (or its representative(s)) submits to FDA a valid waiver before the 45 days elapse, the 505(b)(2) application or ANDA may be approved upon completion of the Agency's review of the NDA or ANDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 45.0 day   | If the patent owner or NDA holder who is an exclusive patent licensee (or its representative(s)) waives its opportunity to file a legal action for patent infringement within 45 days of a receipt of the notice of certification and the patent owner or NDA holder who is an exclusive patent licensee (or its representative(s)) submits to FDA a valid waiver before the 45 days elapse, the 505(b)(2) application or ANDA may be approved upon completion of the Agency's review of the NDA or ANDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 5.0 year   | (2) If a drug product that contains a new chemical entity was approved after September 24, 1984, in an NDA submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act, no person may submit a 505(b)(2) application or ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act for a drug product that contains the same active moiety as in the new chemical entity for a period of 5 years from the date of approval of the first approved NDA, except that the 505(b)(2) application or ANDA may be submitted after 4 years if it contains a certification of patent invalidity or noninfringement described in &#167;&#8201;314.50(i)(1)(i)(A)(4) or &#167;&#8201;314.94(a)(12)(i)(A)(4).                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 4.0 year   | (2) If a drug product that contains a new chemical entity was approved after September 24, 1984, in an NDA submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act, no person may submit a 505(b)(2) application or ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act for a drug product that contains the same active moiety as in the new chemical entity for a period of 5 years from the date of approval of the first approved NDA, except that the 505(b)(2) application or ANDA may be submitted after 4 years if it contains a certification of patent invalidity or noninfringement described in &#167;&#8201;314.50(i)(1)(i)(A)(4) or &#167;&#8201;314.94(a)(12)(i)(A)(4).                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1.0 year   | (3) The approval of a 505(b)(2) application or ANDA described in paragraph (b)(2) of this section will occur as provided in &#167;&#8201;314.107(b)(1) or (2), unless the owner of a patent that claims the drug, the patent owner's representative, or exclusive licensee brings suit for patent infringement against the applicant during the 1-year period beginning 48 months after the date of approval of the NDA for the new chemical entity and within 45 days after receipt of the notice described at &#167;&#8201;314.52 or &#167;&#8201;314.95, in which case, approval of the 505(b)(2) application or ANDA will occur as provided in &#167;&#8201;314.107(b)(3).                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 48.0 month | (3) The approval of a 505(b)(2) application or ANDA described in paragraph (b)(2) of this section will occur as provided in &#167;&#8201;314.107(b)(1) or (2), unless the owner of a patent that claims the drug, the patent owner's representative, or exclusive licensee brings suit for patent infringement against the applicant during the 1-year period beginning 48 months after the date of approval of the NDA for the new chemical entity and within 45 days after receipt of the notice described at &#167;&#8201;314.52 or &#167;&#8201;314.95, in which case, approval of the 505(b)(2) application or ANDA will occur as provided in &#167;&#8201;314.107(b)(3).                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 45.0 day   | (3) The approval of a 505(b)(2) application or ANDA described in paragraph (b)(2) of this section will occur as provided in &#167;&#8201;314.107(b)(1) or (2), unless the owner of a patent that claims the drug, the patent owner's representative, or exclusive licensee brings suit for patent infringement against the applicant during the 1-year period beginning 48 months after the date of approval of the NDA for the new chemical entity and within 45 days after receipt of the notice described at &#167;&#8201;314.52 or &#167;&#8201;314.95, in which case, approval of the 505(b)(2) application or ANDA will occur as provided in &#167;&#8201;314.107(b)(3).                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 3.0 year   | (4) If an NDA:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (i) Was submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (ii) Was approved after September 24, 1984;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (iii) Was for a drug product that contains an active moiety that has been previously approved in another NDA under section 505(b) of the Federal Food, Drug, and Cosmetic Act; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (iv) Contained reports of new clinical investigations (other than bioavailability studies) conducted or sponsored by the applicant that were essential to approval of the application, for a period of 3 years after the date of approval of the application, the Agency will not approve a 505(b)(2) application or an ANDA for the conditions of approval of the NDA, or an ANDA submitted pursuant to an approved petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act that relies on the information supporting the conditions of approval of an original NDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 3.0 year   | (5) If a supplemental NDA:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (i) Was approved after September 24, 1984; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (ii) Contained reports of new clinical investigations (other than bioavailability studies) that were conducted or sponsored by the applicant that were essential to approval of the supplemental NDA, for a period of 3 years after the date of approval of the supplemental application, the Agency will not approve a 505(b)(2) application or an ANDA for a change, or an ANDA submitted pursuant to an approved petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act that relies on the information supporting a change approved in the supplemental NDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 2.0 month  | (i) A resubmission of an application or efficacy supplement that FDA classifies as a Class 1 resubmission constitutes an agreement by the applicant to start a new 2-month review cycle beginning on the date FDA receives the resubmission.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 6.0 month  | (ii) A resubmission of an application or efficacy supplement that FDA classifies as a Class 2 resubmission constitutes an agreement by the applicant to start a new 6-month review cycle beginning on the date FDA receives the resubmission.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 6.0 month  | (iv) A major resubmission of an abbreviated application constitutes an agreement by the applicant to start a new 6-month review cycle beginning on the date FDA receives the resubmission.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 60.0 day   | Within 60 days of the date of the request for an opportunity for a hearing, or within a different time period to which FDA and the applicant agree, the agency will either approve the application or abbreviated application under &#167;&#8201;314.105, or refuse to approve the application under &#167;&#8201;314.125 or abbreviated application under &#167;&#8201;314.127 and give the applicant written notice of an opportunity for a hearing under &#167;&#8201;314.200 and section 505(c)(1)(B) or (j)(5)(c) of the act on the question of whether there are grounds for denying approval of the application or abbreviated application under section 505(d) or (j)(4) of the act, respectively.                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1.0 year   | For an application or abbreviated application, FDA may consider an applicant's failure to take any of such actions within 1 year after issuance of a complete response letter to be a request by the applicant to withdraw the application, unless the applicant has requested an extension of time in which to resubmit the application.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 30.0 day   | The applicant will have 30 days from the date of the notification to explain why the application should not be withdrawn and to request an extension of time in which to resubmit the application.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 30.0 day   | If the applicant does not respond to the notification within 30 days, the application will be deemed to be withdrawn.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 30.0 day   | (iii) Upon the basis of new information before FDA with respect to the drug, evaluated together with the evidence available when the application or abbreviated application was approved, that there is a lack of substantial evidence from adequate and well-controlled investigations as defined in &#167;&#8201;314.126, that the drug will have the effect it is purported or represented to have under the conditions of use prescribed, recommended, or suggested in its labeling; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (iv) That the application or abbreviated application contains any untrue statement of a material fact; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|            |               (v) That the patent information prescribed by section 505(c) of the act was not submitted within 30 days after the receipt of written notice from FDA specifying the failure to submit such information; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (b) FDA may notify the applicant, and, if appropriate, all other persons who manufacture or distribute identical, related, or similar drug products as defined in &#167;&#8201;310.6, and for a new drug afford an opportunity for a hearing on a proposal to withdraw approval of the application or abbreviated new drug application under section 505(e) of the act and under the procedure in &#167;&#8201;314.200, if the agency finds:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (1) That the applicant has failed to establish a system for maintaining required records, or has repeatedly or deliberately failed to maintain required records or to make required reports under section 505(k) or 507(g) of the act and &#167;&#8201;314.80, &#167;&#8201;314.81, or &#167;&#8201;314.98, or that the applicant has refused to permit access to, or copying or verification of, its records.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 30.0 day   | (2) Abbreviated new drug application holders to whom the initial decision was sent may, within 30 days of the issuance of the initial decision, submit written objections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 30.0 day   | (4) If there are no timely objections to the initial decision, it will become final at the expiration of 30 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 30.0 day   | (2) Each abbreviated new drug application holder will have 30 days from the issuance of the initial decision to present, in writing, comments and information bearing on the initial decision.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 30.0 day   | If no comments or information is received, the initial decision will become final at the expiration of 30 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 30.0 day   | (3) Comments and information received within 30 days of the issuance of the initial decision will be considered by the agency and responded to in a final decision.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 30.0 day   | (2) FDA will publish the notice in the Federal Register and will state that the applicant, and other persons subject to the notice under &#167;&#8201;310.6, who wishes to participate in a hearing, has 30 days after the date of publication of the notice to file a written notice of participation and request for hearing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 30.0 day   | The applicant, or other persons subject to the notice under &#167;&#8201;310.6, who fails to file a written notice of participation and request for hearing within 30 days, waives the opportunity for a hearing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 30.0 day   | A person shall request an opinion within 30 days of the date of publication of the notice to be eligible for an opportunity for a hearing under the notice.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 30.0 day   | 1061, Rockville, MD 20852, (i) within 30 days after the date of the publication of the notice (or of the date of receipt of an opinion requested under paragraph (a)(3) of this section) a written notice of participation and request for a hearing and (ii) within 60 days after the date of publication of the notice, unless a different period of time is specified in the notice of opportunity for a hearing, the studies on which the person relies to justify a hearing as specified in paragraph (d) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 60.0 day   | 1061, Rockville, MD 20852, (i) within 30 days after the date of the publication of the notice (or of the date of receipt of an opinion requested under paragraph (a)(3) of this section) a written notice of participation and request for a hearing and (ii) within 60 days after the date of publication of the notice, unless a different period of time is specified in the notice of opportunity for a hearing, the studies on which the person relies to justify a hearing as specified in paragraph (d) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 60.0 day   | (2) FDA will not consider data or analyses submitted after 60 days in determining whether a hearing is warranted unless they are derived from well-controlled studies begun before the date of the notice of opportunity for hearing and the results of the studies were not available within 60 days after the date of publication of the notice.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 60.0 day   | (2) FDA will not consider data or analyses submitted after 60 days in determining whether a hearing is warranted unless they are derived from well-controlled studies begun before the date of the notice of opportunity for hearing and the results of the studies were not available within 60 days after the date of publication of the notice.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 60.0 day   | This person has 60 days after receipt of the proposed order to respond with sufficient data, information, and analyses to demonstrate that there is a genuine and substantial issue of fact which justifies a hearing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 60.0 day   | The person has 60 days after receipt of the proposed order to respond with sufficient data, information, and analyses to demonstrate that there is a genuine and substantial issue of fact which justifies a hearing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 90.0 day   | (5) If the Commissioner grants a hearing, it will begin within 90 days after the expiration of the time for requesting the hearing unless the parties otherwise agree in the case of denial of approval, and as soon as practicable in the case of withdrawal of approval.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 15.0 day   | (1) If the applicant fails to file a written request for a hearing within 15 days of receipt of the notice, the applicant waives the opportunity for a hearing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 30.0 day   | (3) An applicant who requests a hearing under this section must, within 30 days of receipt of the notice of opportunity for a hearing, submit the data and information upon which the applicant intends to rely at the hearing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 120.0 day  | For drug products being considered for approval under this subpart, unless otherwise informed by the agency, applicants must submit to the agency for consideration during the preapproval review period copies of all promotional materials, including promotional labeling as well as advertisements, intended for dissemination or publication within 120 days following marketing approval.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 120.0 day  | After 120 days following marketing approval, unless otherwise informed by the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 30.0 day   | After 120 days following marketing approval, unless otherwise informed by the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 15.0 day   | (1) If the applicant fails to file a written request for a hearing within 15 days of receipt of the notice, the applicant waives the opportunity for a hearing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 30.0 day   | (3) An applicant who requests a hearing under this section must, within 30 days of receipt of the notice of opportunity for a hearing, submit the data and information upon which the applicant intends to rely at the hearing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 120.0 day  | For drug products being considered for approval under this subpart, unless otherwise informed by the agency, applicants must submit to the agency for consideration during the preapproval review period copies of all promotional materials, including promotional labeling as well as advertisements, intended for dissemination or publication within 120 days following marketing approval.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 120.0 day  | After 120 days following marketing approval, unless otherwise informed by the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 30.0 day   | After 120 days following marketing approval, unless otherwise informed by the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |


## Condition

| Condition      | Context                                                                                                                                                            |
|:---------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| subject to     | This part does not apply to drug products subject to licensing by FDA under the Public Health Service                                                              |
| unless         | Regulations are to chapter I of title 21, unless  otherwise noted.                                                                                                 |
| when           | Drug, and Cosmetic Act apply to those terms when used in this part and part 320 of                                                                                 |
| when           | becomes available at the site of drug action when administered at the same molar dose under similar                                                                |
| if             | Where there is an intentional d if ference in rate (e.g., in certain extended-release dosage                                                                       |
| if             | This applies only  if  the d                                                                                                                                       |
| if             | new analyses of previously submitted data (e.g., meta-analyses) if the studies, events, or analyses reveal risks of                                                |
| where          | identity, strength, quality, and purity, including potency and, where  applicable, content uniformity, disintegration times, and/or dissolution rates.             |
| where          | or overage or such forms as prefilled syringes where residual volume may vary, that deliver identical amounts                                                      |
| where          | or overage or such forms as prefilled syringes where residual volume may vary, that deliver identical amounts                                                      |
| if             | raw data from the investigation for FDA audit, if  necessary.                                                                                                      |
| if             | in, delivered, or deliverable from a drug product if the weights and measures described in paragraph (i)                                                           |
| until          | Drug, and Cosmetic Act, but cannot be approved until the conditions in &#167;&#8201;314.107(b)(1)(iii), (b)(3), or (c) are                                         |
| until          | an approved drug and will not be approved until FDA issues an approval letter after any necessary                                                                  |
| when           | have the same clinical effect and safety profile when administered to patients under the conditions specified in                                                   |
| if             | case report forms, drug samples, and labeling, including, if applicable, any Medication Guide required under part 208                                              |
| if             | the date of the NDA; the NDA number if  previously issued (for example,                                                                                            |
| if             | the date of the NDA; the NDA number if  previously issued (for example,                                                                                            |
| when           | of Approval document for public disclosure (under &#167;&#8201;314.430(e)(2)(ii)) when  the NDA is approved.                                                       |
| if             | (i) The proposed text of the labeling, including, if applicable, any Medication Guide required under part 208                                                      |
| if             | (i) The proposed text of the labeling, including, if applicable, any Medication Guide required under part 208                                                      |
| if             | (iii) A brief description of the marketing history,  if any, of the drug outside the United States,                                                                |
| if             | to describe both marketing by the applicant and, if  known, the marketing history of other persons.                                                                |
| unless         | product as required by &#167;&#8201;211.165 of this chapter. unless                                                                                                |
| subject to     | (v) For each nonclinical laboratory study  subject to the good laboratory practice regulations under part 58                                                       |
| if             | good laboratory practice regulations in part 58, or, if the study was not conducted in compliance with                                                             |
| not subject to | review board regulations in part 56, or was not subject to the regulations under &#167;&#8201;56.104 or &#167;&#8201;56.105, and that                              |
| if             | criteria, including data and information supporting the rationale. if                                                                                              |
| when           | other subgroups of the population of patients treated, when appropriate, such as patients with renal failure or                                                    |
| unless         | in analyzing safety data should also be included, unless  already included under paragraph (d)(5)(ii) of this section.                                             |
| if             | and adverse reactions in the draft labeling and, if applicable, any Medication Guide required under part 208                                                       |
| if             | proposal for scheduling under the Controlled Substances Act. if                                                                                                    |
| if             | including information on dialysis, antidotes, or other treatments, if  known.                                                                                      |
| not subject to | review board regulations in part 56, or was not subject to the regulations under &#167;&#8201;56.104 or &#167;&#8201;56.105, and that                              |
| if             | and address of the contract research organization, ident if ication of the clinical study, and a listing                                                           |
| if             | course of monitoring any clinical study to ver if y the accuracy of the case reports submitted                                                                     |
| if             | (ii) Samples of the finished market package,  if  requested by FDA.                                                                                                |
| if             | and all labeling for the drug product (including, if applicable, any Medication Guide required under part 208                                                      |
| if             | requirement may be waived by FDA for spec if ic studies                                                                                                            |
| where          | volume, and page number in the agency's records where  the information can be found.                                                                               |
| if             | report of the investigation submitted in its NDA. if                                                                                                               |
| if             | (ii) The cert if ication must be accompanied by a statement that                                                                                                   |
| if             | Drug, and Cosmetic Act, an appropriate patent cert if ication or statement under this section with respect                                                         |
| if             | 505(b)(2) application is submitted, an appropriate patent cert if ication or statement under this section with respect                                             |
| if             | a proposed indication or other condition of use. if                                                                                                                |
| if             | patent, the applicant must submit an applicable cert if ication under paragraph (i)(1)(i) of this section.                                                         |
| if             | the patent information, contained an appropriate patent cert if ication or statement is not required to submit                                                     |
| if             | applicant who has submitted a paragraph IV cert if ication and is sued for patent infringement must                                                                |
| unless         | includes a finding that the patent is infringed, unless the final decision, settlement order, or consent decree                                                    |
| if             | In its amendment, the applicant must cert if y under paragraph (i)(1)(i)(A)(3) of this section that                                                                |
| until          | to that patent, the patent will remain listed until any 180-day exclusivity based on that patent has                                                               |
| if             | (1) An applicant must amend a submitted cert if ication or statement                                                                                               |
| if             | (1) An applicant must amend a submitted cert if ication or statement                                                                                               |
| when           | submit a supplement to change a submitted certification when information on an otherwise applicable patent is submitted                                            |
| if             | drug for which the applicant is seeking approval. if                                                                                                               |
| if             | the applicant:&#8221; (i) &#8220;New clinical investigations.&#8221; A cert if ication that to the best of the applicant's                                         |
| if             | the approval of its NDA was conducted, ident if ication of the IND by number.                                                                                      |
| if             | which the clinical investigation(s) was conducted, a cert if ication that the applicant or its predecessor in                                                      |
| provided that  | archival copy on paper or in electronic format provided that electronic submissions are made in accordance with part                                               |
| if             | for which the applicant is seeking approval, or, if the NDA holder does not reside or maintain                                                                     |
| if             | may send notice by an alternative method only if FDA has agreed in advance that the method                                                                         |
| if             | by paragraph (a) of this section is invalid if it is sent before the date of filing                                                                                |
| if             | by paragraph (a) of this section is invalid if it is sent before the date of filing                                                                                |
| until          | will not have complied with this paragraph (b) until  it sends valid notice.                                                                                       |
| if             | (3) The established name,  if any, as defined in section 502(e)(3) of the                                                                                          |
| if             | is the subject of the paragraph IV cert if ication.                                                                                                                |
| if             | to accept service of process for the applicant. if                                                                                                                 |
| if             | 505(b)(2) application that includes a paragraph IV cert if ication, the applicant must send the notice required                                                    |
| if             | applicable, an applicant submits a paragraph IV cert if ication in an amendment, the applicant must send                                                           |
| if             | may rely on another form of documentation only if  FDA has agreed to such documentation in advance.                                                                |
| if             | FDA may,  if the applicant amends its 505(b)(2) application with a                                                                                                 |
| if             | claim of patent infringement could reasonably be asserted if a person not licensed by the owner of                                                                 |
| if             | claim of patent infringement could reasonably be asserted if a person not licensed by the owner of                                                                 |
| if             | entirety, the applicant must describe only the spec if ic approved method of use claimed by the                                                                    |
| unless         | We will not accept the patent information  unless it is submitted on the appropriate form, Form                                                                    |
| subject to     | The following information and verification is required,  subject to the exceptions listed in paragraph (c)(2)(i)(S) of this                                        |
| if             | The following information and ver if ication is required, subject to the exceptions listed                                                                         |
| if             | patent owner's name, full address, phone number and, if available, fax number and email address; (I) The                                                           |
| if             | patent owner's name, full address, phone number and, if available, fax number and email address; (I) The                                                           |
| if             | patent owner's name, full address, phone number and, if available, fax number and email address; (I) The                                                           |
| if             | claim of patent infringement could reasonably be asserted if a person not licensed by the owner of                                                                 |
| if             | person; and the full address, phone number and, if available, the fax number and email address; and                                                                |
| if             | person; and the full address, phone number and, if available, the fax number and email address; and                                                                |
| if             | person; and the full address, phone number and, if available, the fax number and email address; and                                                                |
| if             | person; and the full address, phone number and, if available, the fax number and email address; and                                                                |
| if             | FDA will not list or publish patent information  if  it is not provided on this form or                                                                            |
| if             | FDA will not list or publish patent information  if  it is not provided on this form or                                                                            |
| subject to     | The following information and verification statement is required,  subject to the exceptions listed in paragraph (c)(2)(ii)(T) of this                             |
| if             | The following information and ver if ication statement is required, subject to the exceptions                                                                      |
| if             | The following information and ver if ication statement is required, subject to the exceptions                                                                      |
| if             | The following information and ver if ication statement is required, subject to the exceptions                                                                      |
| if             | The following information and ver if ication statement is required, subject to the exceptions                                                                      |
| if             | claim of the patent being submitted; (2) Ident if ication of the spec                                                                                              |
| if             | claim of the patent being submitted; (2) Ident if ication of the spec                                                                                              |
| if             | claim of patent infringement could reasonably be asserted if a person not licensed by the owner of                                                                 |
| if             | person; and the full address, phone number and, if available, the fax number and email address; and                                                                |
| if             | person; and the full address, phone number and, if available, the fax number and email address; and                                                                |
| if             | patent also claims the drug substance (active ingredient). if                                                                                                      |
| if             | requirements of paragraph (d)(2)(ii) of this section apply. if                                                                                                     |
| if             | claim of patent infringement could reasonably be asserted if a person not licensed by the owner of                                                                 |
| when           | and where to submit patent information&#8212;(1) Original NDA. when                                                                                                |
| where          | (d) When and  where  to submit patent information&#8212;(1) Original NDA.                                                                                          |
| if             | information required under paragraph (c) of this section. if                                                                                                       |
| if             | information required under paragraph (c) of this section. if                                                                                                       |
| unless         | information pursuant to paragraph (c) of this section unless the published description of the patented method of                                                   |
| if             | information required under paragraph (c) of this section. if                                                                                                       |
| if             | information required under paragraph (c) of this section. if                                                                                                       |
| if             | with an original NDA, must bear prominent ident if ication as to its contents, i.e., &#8220;Patent Information,&#8221;                                             |
| if             | patent information upon approval of the NDA, or, if the patent information is submitted by the applicant                                                           |
| as soon as     | as provided under paragraph (d)(2) of this section, as soon as possible after the submission to the Agency of                                                      |
| subject to     | or patent information from the list, may be subject to  public disclosure.                                                                                         |
| if             | or amended &#8220;Use Code&#8221; describes only the spec if ic approved method of use claimed by the                                                              |
| if             | of this section, and includes the signed ver if ication required by paragraph (c)(2)(ii)(R) of this section                                                        |
| if             | of this section, and includes the signed ver if ication required by paragraph (c)(2)(ii)(R) of this section                                                        |
| if             | the Federal Food, Drug, and Cosmetic Act (including if there has been a judicial finding of invalidity                                                             |
| if             | a patent or patent information from the list if there is no first applicant eligible for 180-day                                                                   |
| unless         | We will not accept the corrections or changes  unless  they are submitted on the appropriate forms.                                                                |
| if             | approval of other changes in a listed drug if investigations, other than bioavailability or bioequivalence studies, are                                            |
| if             | (iii) Ident if ication of each listed drug for which FDA                                                                                                           |
| if             | drug on which the applicant relies, a cert if ication so stating.                                                                                                  |
| if             | claim of patent infringement could reasonably be asserted if a person not licensed by the owner of                                                                 |
| if             | period of exclusivity, the information required under &#167;&#8201;314.50(j). if                                                                                   |
| when           | described in &#167;&#8201;314.50(d)(2), (d)(4) through (6), and (f) when  needed to support the modification.                                                      |
| if             | not be needed in each pediatric age group, if data from one age group can be extrapolated                                                                          |
| until          | effectiveness described in paragraph (a) of this section until after approval of the drug product for use                                                          |
| if             | Deferral may be granted  if , among other reasons, the drug is ready                                                                                               |
| until          | are complete, or pediatric studies should be delayed until  additional safety or effectiveness data have been collected.                                           |
| if             | FDA determines that there is an adequate just if ication for temporarily delaying the submission of assessments                                                    |
| subject to     | product may be approved for use in adults subject to the requirement that the applicant submit the required                                                        |
| if             | the requirements of paragraph (a) of this section if  the applicant cert                                                                                           |
| if             | of this section with respect to a spec if ied pediatric age group,                                                                                                 |
| if             | grant a full or partial waiver, as appropriate, if the agency finds that there is a reasonable                                                                     |
| if             | offer a meaningful therapeutic benefit over existing therapies if FDA estimates that: (i) If approved, the drug                                                    |
| if             | offer a meaningful therapeutic benefit over existing therapies if FDA estimates that: (i) If approved, the drug                                                    |
| when           | FDA generally assumes that  when an original NDA, supplement to an approved NDA,                                                                                   |
| until          | FDA may instead defer review of the amendment until  the subsequent review cycle.                                                                                  |
| until          | initial review cycle (as extended) or defer review until  the subsequent review cycle.                                                                             |
| until          | during the initial review cycle or defer review until  the subsequent review cycle.                                                                                |
| until          | during the initial review cycle or defer review until  the subsequent review cycle.                                                                                |
| until          | FDA may instead defer review of the amendment  until  the subsequent review cycle.                                                                                 |
| until          | initial review cycle (as extended) or defer review until  the subsequent review cycle.                                                                             |
| until          | during the initial review cycle or defer review until  the subsequent review cycle.                                                                                |
| when           | to the applicant under &#167;&#8201;314.110 of this part. when                                                                                                     |
| until          | (7) When FDA defers review of an amendment  until the subsequent review cycle, the agency will notify                                                              |
| if             | (1) An unapproved NDA may not be amended  if all of the following conditions apply: (i) The                                                                        |
| if             | this paragraph (e), a drug is a d if ferent drug                                                                                                                   |
| if             | is required to contain an appropriate patent cert if ication or statement described in &#167;&#8201;314.50(i) or a                                                 |
| if             | 505(b)(2) application does not contain a patent cert if ication or statement, the applicant must ver                                                               |
| if             | chapter, except for changes in the information spec if ied in &#167;&#8201;208.20(b)(8)(iii) and (b)(8)(iv) of this chapter;                                       |
| subject to     | a drug product under an NDA that is subject to a validity assessment because of significant questions regarding                                                    |
| if             | of a supplement for public health reasons or if a delay in making the change described in                                                                          |
| if             | labeled &#8220;Supplement&#8212;Changes Being Effected in 30 Days&#8221; or, if applicable under paragraph (c)(6) of this section, &#8220;Supplement&#8212;Changes |
| if             | distribute the drug product made using the change if within 30 days following FDA's receipt of the                                                                 |
| until          | distribute the drug product made using the change until the supplement has been amended to provide the                                                             |
| if             | the drug product(s) made with the manufacturing change. if                                                                                                         |
| if not         | Any such protocols,  if not included in the approved NDA, or changes to                                                                                            |
| if             | The supplement,  if  approved, may subsequently just                                                                                                               |
| if             | this paragraph (h), a drug is a d if ferent drug                                                                                                                   |
| when           | may be considered a serious adverse drug experience when , based upon appropriate medical judgment, they may                                                       |
| if             | would be unexpected (by virtue of greater severity) if the labeling only referred to elevated hepatic enzymes                                                      |
| if             | would be unexpected (by virtue of greater spec if icity)                                                                                                           |
| subject to     | Any person  subject to the reporting requirements under paragraph (c) of this                                                                                      |
| as soon as     | both serious and unexpected, whether foreign or domestic, as soon as possible but no later than 15 calendar days                                                   |
| unless         | not conducted under an investigational new drug application) unless the applicant concludes that there is a reasonable                                             |
| if             | is a health care professional; and (iii) Occupation, if  a health care professional.                                                                               |
| if             | adverse drug experiences that occurred in clinical trials if they were previously submitted as part of the                                                         |
| when           | as part of the initial reporter information, even when  the reporter is the patient.                                                                               |
| if             | the order in which they were implemented, or if  no changes, a statement of that fact.                                                                             |
| if             | shall submit a copy of a published report if  requested by FDA.                                                                                                    |
| if             | of completed unpublished clinical trials, or prepublication manuscripts if available, conducted by, or otherwise obtained by, the                                  |
| until          | of these postmarketing studies shall be reported annually until FDA notifies the applicant, in writing, that the                                                   |
| if             | approved drug product's established name and proprietary name, if  any.                                                                                            |
| if             | as well as the reason(s) for the revision, if the schedule under paragraph (b)(2)(vii)(a)(7) of this section                                                       |
| if             | (b)(2)(vii) of this section, concerning a postmarketing study, if the agency determines that the information is necessary                                          |
| if             | (b)(2)(vii) of this section, concerning a postmarketing study, if the agency determines that the information is necessary                                          |
| subject to     | regulatory business with FDA concerning the drug product subject to the application (e.g., a list of the applicant's                                               |
| if             | (b) Not if ications required by paragraph (b)(3)(iii)(a) of this section                                                                                           |
| as soon as     | was not reasonably anticipated 6 months in advance, as soon as practicable thereafter, but in no case later than                                                   |
| subject to     | following information: (1) The name of the drug subject to the notification, including the NDC for such drug;                                                      |
| if             | Food, Drug, and Cosmetic Act (21 U.S.C. 356c(c)) if FDA determines that disclosure of such information would                                                       |
| if             | If an applicant fails to submit a not if ication as required under paragraph (b)(3)(iii)(a) of this                                                                |
| unless         | and the applicant's response to the letter public, unless , after review of the applicant's response, FDA                                                          |
| when           | shortage or shortage means a period of time when the demand or projected demand for the drug                                                                       |
| subject to     | sale, applicants who are manufacturers, repackers, or relabelers subject to part 207 of this chapter must submit the                                               |
| if             | drug by established name and by proprietary name, if any; (3) The new drug application number or                                                                   |
| not subject to | an approved drug from sale, applicants who are not subject to part 207 of this chapter must submit the                                                             |
| when           | of individual patients; this will ordinarily occur only when the agency needs to investigate the reports further                                                   |
| when           | of individual patients; this will ordinarily occur only when the agency needs to investigate the reports further                                                   |
| if             | (b) FDA may grant a waiver  if it finds one of the following: (1) The                                                                                              |
| if             | for refusal to approve an NDA under &#167;&#8201;314.125. if                                                                                                       |
| when           | identify more than one listed drug, for example, when the proposed drug product is a combination product                                                           |
| when           | same therapeutic effect as the reference listed drug when administered to patients for each condition of use                                                       |
| if             | product is a combination product with one d if ferent active ingredient, including a d                                                                             |
| unless         | approve a petition properly submited under this section unless it finds that: (i) Investigations must be conducted                                                 |
| when           | same therapeutic effect as the reference listed drug when administered to patients for each condition of use                                                       |
| if             | the agency's response may describe what additional information, if any, will be required to support an ANDA                                                        |
| if             | the agency's response may describe what additional information, if any, will be required to support an ANDA                                                        |
| if             | (f)(1) FDA may withdraw approval of a petition  if the agency receives any information demonstrating that the                                                      |
| if             | petition, the petition and the listed drug ident if ied in the petition can no longer be                                                                           |
| if             | the reference listed drug except for any d if ferent active ingredient that has been the subject                                                                   |
| if             | form, or strength of the drug product d if fers from the reference listed drug and the                                                                             |
| if             | same therapeutic effect as the reference listed drug. if                                                                                                           |
| if             | If the proposed drug product contains a d if ferent active ingredient than the reference listed drug,                                                              |
| not subject to | in part 56 of this chapter, or was not subject to the regulations under &#167;&#8201;56.104 or &#167;&#8201;56.105 of this                                         |
| if             | A copy of the currently approved labeling (including,  if applicable, any Medication Guide required under part 208                                                 |
| if             | A copy of the currently approved labeling (including,  if applicable, any Medication Guide required under part 208                                                 |
| if             | and all labeling for the drug product including, if applicable, any Medication Guide required under part 208                                                       |
| if             | A statement that the applicant's proposed labeling including,  if applicable, any Medication Guide required under part 208                                         |
| if             | side-by-side comparison of the applicant's proposed labeling including, if applicable, any Medication Guide required under part 208                                |
| if             | Labeling (including the container label, package insert, and,  if applicable, Medication Guide) proposed for the drug product                                      |
| provided that  | reference listed drug in preservative, buffer, or antioxidant provided that the applicant identifies and characterizes the differences and                         |
| provided that  | buffer, substance to adjust tonicity, or thickening agent provided that the applicant identifies and characterizes the differences and                             |
| provided that  | However, an ANDA may include different inactive ingredients  provided that the applicant identifies and characterizes the differences and                          |
| until          | Samples need not be submitted  until  requested by FDA.                                                                                                            |
| if             | (ii) The cert if ication must be accompanied by a statement that                                                                                                   |
| if             | Drug, and Cosmetic Act, an appropriate patent cert if ication or statement under paragraph (a)(12)(i) and/or (iii)                                                 |
| if             | a proposed indication or other condition of use. if                                                                                                                |
| if             | claimed by a method-of-use patent, an applicable cert if ication under paragraph (a)(12)(i) of this section.                                                       |
| if             | that drug that contained an appropriate patent cert if ication or statement before the submission of the                                                           |
| if             | applicant who has submitted a paragraph IV cert if ication and is sued for patent infringement must                                                                |
| unless         | includes a finding that the patent is infringed, unless the final decision, settlement order, or consent decree                                                    |
| if             | In its amendment, the applicant must cert if y under paragraph (a)(12)(i)(A)(3) of this section that                                                               |
| until          | to that patent, the patent will remain listed until any 180-day exclusivity based on that patent has                                                               |
| if             | (i) An applicant must amend a submitted cert if ication or statement                                                                                               |
| if             | (i) An applicant must amend a submitted cert if ication or statement                                                                                               |
| when           | submit a supplement to change a submitted certification when information on a patent on the listed drug                                                            |
| subject to     | (b) Drug products  subject to  the Drug Efficacy Study Implementation (DESI) review.                                                                               |
| subject to     | a duplicate of a drug product that is subject to FDA's DESI review (a review of drug products                                                                      |
| if             | for which the applicant is seeking approval, or, if the NDA holder does not reside or maintain                                                                     |
| if             | may send notice by an alternative method only if FDA has agreed in advance that the method                                                                         |
| if             | by paragraph (a) of this section is invalid if it is sent before the applicant's receipt of                                                                        |
| until          | will not have complied with this paragraph (b) until  it sends valid notice.                                                                                       |
| if             | (4) The established name,  if any, as defined in section 502(e)(3) of the                                                                                          |
| if             | is the subject of the paragraph IV cert if ication.                                                                                                                |
| if             | to accept service of process for the applicant. if                                                                                                                 |
| if             | its ANDA that includes a paragraph IV cert if ication, the applicant must send the notice required                                                                 |
| if             | its ANDA that includes a paragraph IV cert if ication, the applicant must send the notice required                                                                 |
| if             | may rely on another form of documentation only if  FDA has agreed to such documentation in advance.                                                                |
| if             | FDA may,  if the applicant provides a written statement to FDA                                                                                                     |
| unless         | the applicant on the same drug product formulation, unless the information has previously been submitted to FDA                                                    |
| if             | This paragraph (c) applies  if , at any time before the approval of                                                                                                |
| if             | This paragraph (c) also applies  if changes are proposed in an amendment to the                                                                                    |
| if             | is required to contain an appropriate patent cert if ication or statement described in &#167;&#8201;314.94(a)(12) or a                                             |
| if             | the ANDA does not contain a patent cert if ication or statement, the applicant must ver                                                                            |
| if             | This paragraph (b) applies  if changes are proposed in a supplement to the                                                                                         |
| if             | the Agency will file the NDA and not if y the applicant in writing.                                                                                                |
| if             | to file the NDA, the Agency will not if y the applicant in writing and state the                                                                                   |
| if             | the Agency will receive the ANDA and not if y the applicant in writing.                                                                                            |
| if             | or (e) of this section, FDA will not if y the applicant of the refuse-to-receive decision.                                                                         |
| if             | may not consider an ANDA to be received if any of the following applies: (1) The NDA                                                                               |
| subject to     | information to establish that the requested action is subject to categorical exclusion under &#167;&#8201;25.30 or &#167;&#8201;25.31 of this                      |
| not subject to | in part 56 of this chapter, or was not subject to those regulations, and that it was conducted in                                                                  |
| if             | regulations in part 50 of this chapter, or, if the study was subject to but was not                                                                                |
| subject to     | part 56 of this chapter, or was not subject to those regulations, and that it was conducted in                                                                     |
| if             | consider an ANDA not to have been received if  any of the following applies:                                                                                       |
| subject to     | (1) The drug product is  subject to licensing by FDA under the Public Health Service                                                                               |
| if             | of time the review period was extended ( if any), FDA will either: (i) Approve the NDA;                                                                            |
| if             | will issue a notice of opportunity for hearing if the applicant asked FDA to provide it an                                                                         |
| when           | found in an application or an abbreviated application when those deficiencies are discovered, particularly deficiencies concerning chemistry,                      |
| if             | applicant's option, and may be held by telephone if  mutually agreed upon.                                                                                         |
| if             | (1) Because major scient if ic issues are ordinarily communicated to applicants in                                                                                 |
| if             | provide a timely forum for discussing and resolving, if  possible, issues ident                                                                                    |
| when           | the matter directly with the responsible reviewing officials. when                                                                                                 |
| if             | Office Director, and finally with the Center Director if  the matter is still unresolved.                                                                          |
| when           | of the Controlled Substances Act (21 U.S.C. 801) when an application or abbreviated application is submitted for                                                   |
| if             | NDA and send the applicant an approval letter if none of the reasons in &#167;&#8201;314.125 for refusing                                                          |
| if             | FDA will issue a tentative approval letter  if an NDA otherwise meets the requirements for approval                                                                |
| if             | FDA will issue a tentative approval letter  if an NDA otherwise meets the requirements for approval                                                                |
| until          | Drug, and Cosmetic Act, but cannot be approved until the conditions in &#167;&#8201;314.107(b)(3) are met; because there                                           |
| until          | an approved drug and will not be approved until FDA issues an approval after any necessary additional                                                              |
| subject to     | testing of the drug product) and is therefore subject to change on the basis of new information that                                                               |
| until          | A new drug product may not be marketed  until  the date of approval.                                                                                               |
| if             | approval letter on the basis of draft labeling if the only deficiencies in the NDA concern editorial                                                               |
| where          | statutory standards for manufacturing and controls, labeling, and, where  applicable, bioequivalence.                                                              |
| subject to     | drugs, the many kinds of drugs that are subject to the statutory standards and the wide range of                                                                   |
| if             | ANDA and send the applicant an approval letter if none of the reasons in &#167;&#8201;314.127 for refusing                                                         |
| if             | FDA will issue a tentative approval letter  if an ANDA otherwise meets the requirements for approval                                                               |
| until          | &#167;&#8201;316.31 of this chapter, or cannot be approved until the conditions in &#167;&#8201;314.107(b)(3) or (c) are met;                                      |
| until          | an approved drug and will not be approved until FDA issues an approval after any necessary additional                                                              |
| subject to     | testing of the drug product) and is therefore subject to change on the basis of new information that                                                               |
| until          | A new drug product may not be marketed  until  the date of approval.                                                                                               |
| if             | U.S. criteria for marketing approval may be approved if : (1) The foreign data are applicable to                                                                   |
| when           | meet with agency officials in a &#8220;presubmission&#8221; meeting when approval based solely on foreign data will be                                             |
| when           | introduced or delivered for introduction into interstate commerce when the 505(b)(2) application or ANDA for the drug                                              |
| if             | ANDA may be approved as follows: (i) Immediately, if  the applicant cert                                                                                           |
| if             | (ii) Immediately,  if the applicant submits an appropriate statement under &#167;&#8201;314.50(i)                                                                  |
| if             | (ii) Immediately,  if the applicant submits an appropriate statement under &#167;&#8201;314.50(i)                                                                  |
| if             | (iii) On the date spec if ied,                                                                                                                                     |
| if             | in paragraphs (b)(3)(ii) through (viii) of this section, if , with respect to patents for which required                                                           |
| unless         | or by the NDA holder (or its representative(s)) unless the court has extended or reduced the period                                                                |
| if             | in paragraphs (b)(3)(ii) through (viii) of this section, if , with respect to patents for which required                                                           |
| where          | expiration of the 30-month period, or 71/2 years where applicable, the district court decides that the patent                                                      |
| where          | expiration of the 30-month period, or 71/2 years where applicable, the district court decides that the patent                                                      |
| if             | decides that the patent has been infringed, and if the judgment of the district court is appealed,                                                                 |
| where          | expiration of the 30-month period, or 71/2 years where applicable, the district court decides that the patent                                                      |
| if             | decides that the patent has been infringed, and if the judgment of the district court is not                                                                       |
| where          | expiration of the 30-month period, or 71/2 years where applicable, the district court grants a preliminary injunction                                              |
| until          | commercial manufacture or sale of the drug product until the court decides the issues of patent validity                                                           |
| if             | the issues of patent validity and infringement, and if the court later decides that: (A) The patent                                                                |
| where          | expiration of the 30-month period, or 71/2 years where applicable, the patent owner or the exclusive patent                                                        |
| where          | expiration of the 30-month period, or 71/2 years where applicable, the court enters an order requiring the                                                         |
| where          | expiration of the 30-month period, or 71/2 years where applicable, the court(s) enter(s) an order of dismissal,                                                    |
| when           | FDA will issue a tentative approval letter  when tentative approval is appropriate in accordance with this                                                         |
| if             | If an ANDA contains a paragraph IV cert if ication for a relevant patent and the ANDA                                                                              |
| when           | applicant will not be approved during the period when any first applicant is eligible for 180-day exclusivity                                                      |
| if             | immediately approve an ANDA(s) of a subsequent applicant(s) if  the ANDA(s) is otherwise eligible for approval.                                                    |
| if             | immediately approve an ANDA(s) of a subsequent applicant(s) if  the ANDA(s) is otherwise eligible for approval.                                                    |
| if             | the approval of a 505(b)(2) application or ANDA if delay is required by the exclusivity provisions in                                                              |
| if             | The established name of the drug product or, if no established name exists, the name(s) of the                                                                     |
| if             | NDA holder, or its representative(s) does not not if y FDA in writing before the expiration of                                                                     |
| if             | will convert the approval to a tentative approval if  appropriate.                                                                                                 |
| if             | support,&#8221; an applicant must either provide a cert if ied statement from a cert                                                                               |
| if             | or ANDA may be submitted after 4 years if  it contains a cert                                                                                                      |
| if             | or ANDA may be submitted after 4 years if  it contains a cert                                                                                                      |
| unless         | will occur as provided in &#167;&#8201;314.107(b)(1) or (2), unless the owner of a patent that claims the                                                          |
| if             | the conditions of approval of an original NDA. if                                                                                                                  |
| if             | supporting a change approved in the supplemental NDA. if                                                                                                           |
| if             | will send the applicant a complete response letter if the agency determines that we will not approve                                                               |
| where          | in an original application or abbreviated application (or, where appropriate, a resubmission) and any amendments that the                                          |
| until          | under section 505(c)(1) or (j)(5)(A) of the act until it takes any of the actions listed in                                                                        |
| unless         | request by the applicant to withdraw the application, unless the applicant has requested an extension of time                                                      |
| if             | to withdraw the application, the agency will not if y the applicant in writing.                                                                                    |
| when           | reasons, in accordance with the procedures in &#167;&#8201;314.161. when                                                                                           |
| unless         | of this section will be disapproved, under &#167;&#8201;314.93(e)(1)(iv), unless the agency determines that the withdrawal of the                                  |
| unless         | an NDA for any of the following reasons, unless the requirement has been waived under &#167;&#8201;314.90: (1)                                                     |
| if             | letter refusing to file the NDA under &#167;&#8201;314.101(d), if  the deficiency is not corrected.                                                                |
| if             | no reason for the noncompliance is provided or, if  it is, the d                                                                                                   |
| subject to     | investigation involving human subjects described in the NDA, subject to the institutional review board regulations in part 56                                      |
| when           | of the drug products used in the study when  requested by FDA.                                                                                                     |
| where          | is compared with known effective therapy; for example, where the condition treated is such that administration of                                                  |
| if             | to set forth clearly and concisely the spec if ic criteria from which waiver is sought, why                                                                        |
| unless         | Cosmetic Act for any of the following reasons, unless the requirement has been waived under &#167;&#8201;314.99: (1)                                               |
| if             | drug has more than one active ingredient and if the ANDAis for a drug product that has                                                                             |
| if             | drug has more than one active ingredient and if the ANDAis for a drug product that has                                                                             |
| if             | drug has more than one active ingredient and if the ANDAis for a drug product that has                                                                             |
| if             | drug has more than one active ingredient and if the ANDAis for a drug product that has                                                                             |
| if             | of administration, dosage form, or strength is d if ferent from that of the listed drug referred                                                                   |
| if             | of administration, dosage form, or strength is d if ferent from that of the listed drug referred                                                                   |
| if             | same as that of the reference listed drug. if                                                                                                                      |
| if             | of use approved for the reference listed drug. if                                                                                                                  |
| when           | same therapeutic effect as the reference listed drug when administered to patients for each condition of use                                                       |
| if             | an ANDA under paragraph (a)(8)(i) of this section if , on the basis of information available to                                                                    |
| if             | to raise serious questions of safety or efficacy if the product incorporates one or more of these                                                                  |
| if             | oleaginous to a water soluble vehicle or base. if                                                                                                                  |
| unless         | unsafe and will refuse to approve the ANDA unless it contains the same inactive ingredients, other than                                                            |
| if             | the same concentration as the listed drug, and, if  it d                                                                                                           |
| unless         | unsafe and will refuse to approve the ANDA unless it contains the same inactive ingredients, other than                                                            |
| if             | the same concentration as the listed drug, and if  it d                                                                                                            |
| if             | to approve an ANDA for a new drug if the applicant or contract research organization that conducted                                                                |
| when           | of the drug products used in the study when  requested by FDA.                                                                                                     |
| if             | (a) The Food and Drug Administration will not if y the applicant, and,                                                                                             |
| if             | (a) The Food and Drug Administration will not if y the applicant, and,                                                                                             |
| until          | in the application or not available to FDA until after the application or abbreviated application was approved,                                                    |
| when           | or tests by methods not deemed reasonably applicable when the application or abbreviated application was approved, evaluated                                       |
| when           | or tests by methods not deemed reasonably applicable when the application or abbreviated application was approved, evaluated                                       |
| when           | the drug, evaluated together with the evidence available when the application or abbreviated application was approved, that                                        |
| if             | the receipt of written notice from FDA spec if ying the failure to submit such information; or                                                                     |
| if             | the receipt of written notice from FDA spec if ying the failure to submit such information; or                                                                     |
| when           | before FDA, evaluated together with the evidence available when the application or abbreviated application was approved, the                                       |
| when           | before FDA, evaluated together with the evidence available when the application or abbreviated application was approved, the                                       |
| if             | no reason for the noncompliance was provided or, if  it was, the d                                                                                                 |
| subject to     | subjects described in the application or abbreviated application, subject to the institutional review board regulations in part 56                                 |
| when           | of the drug products used in the study when  requested by FDA.                                                                                                     |
| if             | withdraw approval of an application or abbreviated application if the applicant requests its withdrawal because the drug                                           |
| subject to     | the applicant requests its withdrawal because the drug subject to the application or abbreviated application is no longer                                          |
| when           | drug application approved under &#167;&#8201;314.105(d) may be withdrawn when the agency withdraws approval, under &#167;&#8201;314.150(a) or under                |
| subject to     | drug products approved under &#167;&#8201;314.105(d) whose applications are subject to withdrawal under this section if the listed drug                            |
| if             | published notice of opportunity for hearing will ident if y all drug products approved under &#167;&#8201;314.105(d) whose                                         |
| when           | withdrawal of a listed drug will be withdrawn when the agency has completed the withdrawal of approval                                                             |
| if             | holder of an application for a drug ident if ied in the notice of opportunity for hearing                                                                          |
| if             | become final at the expiration of 30 days. if                                                                                                                      |
| if             | reviewed and responded to in a final decision. if                                                                                                                  |
| if             | decision, the objections to the initial decision, and, if a limited oral hearing has been held, the                                                                |
| if             | drug are not applicable to a drug ident if ied in the notice of opportunity for hearing,                                                                           |
| until          | in the decision and will remain in effect until the agency determines that the marketing of the                                                                    |
| when           | Procedures for suspension of abbreviated new drug applications when a listed drug is voluntarily withdrawn for safety                                              |
| if             | decision setting forth the reasons for the determination. if                                                                                                       |
| subject to     | an approved abbreviated new drug application that is subject to suspension as a result of this determination a                                                     |
| if             | approval of all abbreviated new drug applications ident if ied under paragraph (b)(1) of this section and                                                          |
| if             | such abbreviated new drug application is not suspended. if                                                                                                         |
| subject to     | to the safety and effectiveness of the drug subject to such abbreviated new drug application, the final decision                                                   |
| when           | determination under &#167;&#167;&#8201;10.25(a) and 10.30 of this chapter. when                                                                                    |
| if             | notice of the determination in the Federal Register. if                                                                                                            |
| if             | will initiate a proceeding in accordance with &#167;&#8201;314.153(b). if                                                                                          |
| subject to     | are approved abbreviated new drug applications that are subject to suspension under section 505(j)(5) of the act, FDA                                              |
| if             | The drug may be relisted  if the agency has evidence that marketing of the                                                                                         |
| until          | safety or effectiveness reasons, or suspended under &#167;&#8201;314.153(b), until the agency determines that the withdrawal from the                              |
| subject to     | 505 of the act and this part, are subject to the adulteration and misbranding provisions in sections 501,                                                          |
| subject to     | will state that the applicant, and other persons subject to the notice under &#167;&#8201;310.6, who wishes to participate                                         |
| subject to     | The applicant, or other persons  subject to the notice under &#167;&#8201;310.6, who fails to file                                                                 |
| subject to     | a hearing to applicants and to other persons subject to the notice under &#167;&#8201;310.6, as follows: (1) To                                                    |
| subject to     | an application or abbreviated application but who is subject to the notice under &#167;&#8201;310.6 of this chapter, by                                            |
| subject to     | The applicant, or any other person  subject to the notice under &#167;&#8201;310.6, who wishes to participate                                                      |
| unless         | after the date of publication of the notice, unless a different period of time is specified in                                                                     |
| if             | by reference the raw data underlying a study if the data were previously submitted to FDA as                                                                       |
| unless         | days in determining whether a hearing is warranted unless they are derived from well-controlled studies begun before                                               |
| not subject to | (3) Any other interested person who is  not subject to the notice of opportunity for a hearing may                                                                 |
| if             | not required to submit additional studies and analyses if the studies upon which the person relies have                                                            |
| if             | has been previously granted by FDA under &#167;&#8201;314.126. if                                                                                                  |
| if             | the drug, the analysis is required to spec if y how each study accords, on a point-by-point                                                                        |
| if             | to safety or to effectiveness may be omitted if the notice of opportunity for hearing does not                                                                     |
| if             | to safety or to effectiveness may be omitted if the notice of opportunity for hearing does not                                                                     |
| not subject to | (e) Contentions that a drug product is  not subject to  the new drug requirements.                                                                                 |
| subject to     | to the legal status of each drug product subject to it, including identical, related, and similar drug products                                                    |
| subject to     | The failure of any person  subject to a notice of opportunity for a hearing, including                                                                             |
| unless         | obtain approval of an application for the product, unless FDA has waived a requirement for effectiveness (under                                                    |
| subject to     | The ruling on such a motion is  subject to  review in accordance with &#167;&#8201;12.35(b).                                                                       |
| where          | of this chapter, showing effectiveness have been identified. where                                                                                                 |
| if             | (1) Where a spec if ic notice of opportunity for hearing (as defined                                                                                               |
| when           | registered mail a proposed order denying a hearing. when                                                                                                           |
| when           | registered mail a proposed order denying a hearing. when                                                                                                           |
| if             | and rescind the notice of opportunity for hearing. if                                                                                                              |
| if             | practicable in the case of withdrawal of approval. if                                                                                                              |
| unless         | expiration of the time for requesting the hearing unless the parties otherwise agree in the case of                                                                |
| as soon as     | in the case of denial of approval, and as soon as  practicable in the case of withdrawal of approval.                                                              |
| if             | (6) The Commissioner will grant a hearing  if there exists a genuine and substantial issue of                                                                      |
| if             | (6) The Commissioner will grant a hearing  if there exists a genuine and substantial issue of                                                                      |
| if             | in the notice of opportunity for a hearing. if                                                                                                                     |
| subject to     | and declaring all products unlawful for drug products subject to a notice of opportunity for a hearing, including                                                  |
| if             | drug may be imported into the United States if it complies with the labeling exemption in &#167;&#8201;201.122                                                     |
| if             | (1) A new drug may be exported  if it is the subject of an approved application                                                                                    |
| if             | the requirements in section 802 of the act if the insulin or antibiotic drug meets the requirements                                                                |
| when           | the holder to incorporate the information by reference when the holder submits an investigational new drug application                                             |
| if             | drug master file in support of the submission if  the holder authorizes the incorporation in writing.                                                              |
| if             | of each drug product and the application number, if  known, to which the authorization applies.                                                                    |
| unless         | letter is sent to the applicant under &#167;&#8201;314.107, unless the existence of the application or abbreviated application                                     |
| if             | or abbreviated application is available for public disclosure. if                                                                                                  |
| if             | are appropriate for public consideration of a spec if ic pending issue; for example, for consideration of                                                          |
| unless         | abbreviated application are immediately available for public disclosure, unless  the applicant shows that extraordinary circumstances exist.                       |
| if             | with or incorporated by reference in the application. if                                                                                                           |
| unless         | (3) A protocol for a test or study,  unless it is shown to fall within the exemption                                                                               |
| unless         | (6) An assay procedure or other analytical procedure,  unless it serves no regulatory or compliance purpose and                                                    |
| unless         | time any one of the following events occurs unless extraordinary circumstances are shown: (1) No work is                                                           |
| if             | refers to such drug could be made effective if  such an abbreviated application had been submitted.                                                                |
| when           | applications submitted under section 505(j) of the act, when  FDA sends an approval letter to the applicant.                                                       |
| unless         | abbreviated application are not available for public disclosure unless they have been previously disclosed to the public                                           |
| subject to     | Approval under this section will be  subject to the requirement that the applicant study the drug                                                                  |
| where          | further, to verify and describe its clinical benefit, where there is uncertainty as to the relation of                                                             |
| if             | to be effective can be safely used only if distribution or use is restricted, FDA will require                                                                     |
| if             | to be effective can be safely used only if distribution or use is restricted, FDA will require                                                                     |
| if             | the applicant waives the opportunity for a hearing. if                                                                                                             |
| if             | accordance with &#167;&#167;&#8201;12.32(e) and 15.20 of this chapter. if                                                                                          |
| subject to     | Drug products approved under this program are  subject to the postmarketing recordkeeping and safety reporting applicable to                                       |
| unless         | products being considered for approval under this subpart, unless otherwise informed by the agency, applicants must submit                                         |
| unless         | After 120 days following marketing approval,  unless otherwise informed by the agency, the applicant must                                                          |
| when           | under &#167;&#8201;314.510, these requirements will no longer apply when FDA determines that the required postmarketing study verifies                             |
| when           | under &#167;&#8201;314.520, the restrictions would no longer apply when FDA determines that safe use of the drug                                                   |
| when           | met based on adequate and well-controlled animal studies when the results of those animal studies establish that                                                   |
| unless         | to react with a response predictive for humans, unless the effect is demonstrated in a single animal                                                               |
| subject to     | (b) Approval under this subpart will be  subject to  three requirements:                                                                                           |
|                |               (1) Postmarketing studies.                                                                                                                           |
| when           | drug's clinical benefit and to assess its safety when  used as indicated                                                                                           |
| when           | drug's clinical benefit and to assess its safety when  used as indicated                                                                                           |
| until          | Such postmarketing studies would not be feasible  until  an exigency arises.                                                                                       |
| if             | under this subpart can be safely used only if distribution or use is restricted, FDA will require                                                                  |
| if             | product for the use approved under this subpart, if  possible.                                                                                                     |
| if             | the applicant waives the opportunity for a hearing. if                                                                                                             |
| if             | accordance with &#167;&#167;&#8201;12.32(e) and 15.20 of this chapter. if                                                                                          |
| subject to     | Drug products approved under this subpart are  subject to the postmarketing recordkeeping and safety reporting requirements applicable                             |
| unless         | products being considered for approval under this subpart, unless otherwise informed by the agency, applicants must submit                                         |
| unless         | After 120 days following marketing approval,  unless otherwise informed by the agency, the applicant must                                                          |
| when           | under &#167;&#8201;314.610, these requirements will no longer apply when FDA determines that the postmarketing study verifies and                                  |
| when           | under &#167;&#8201;314.610, the restrictions would no longer apply when FDA determines that safe use of the drug                                                   |


## Entities

| Entities                                                   | Context                                                                                                                                 |
|:-----------------------------------------------------------|:----------------------------------------------------------------------------------------------------------------------------------------|
| Food                                                       | Food  and Drugs.                                                                                                                        |
| Scope                                                      | Scope  of this part.                                                                                                                    |
| Purpose                                                    | Purpose .                                                                                                                               |
| Abbreviated                                                | Abbreviated application, abbreviated new drug application, or ANDA is                                                                   |
| Active                                                     | Active ingredient is any component that is intended to                                                                                  |
| Active                                                     | Active moiety is the molecule or ion, excluding those                                                                                   |
| Applicant                                                  | Applicant is any person who submits an NDA (including                                                                                   |
| Application                                                | Application , new drug application, or NDA is the                                                                                       |
| Approval                                                   | Approval letter is a written communication to an applicant                                                                              |
| Authorized                                                 | Authorized generic drug is a listed drug, as defined                                                                                    |
| Bioavailability                                            | Bioavailability is the rate and extent to which the                                                                                     |
| Bioequivalence                                             | Bioequivalence is the absence of a significant difference in                                                                            |
| Bioequivalence                                             | Bioequivalence requirement is a requirement imposed by FDA for                                                                          |
| Dosage                                                     | Dosage form is the physical manifestation containing the active                                                                         |
| Drug                                                       | Drug product is a finished dosage form, e.g., tablet,                                                                                   |
| Drug                                                       | Drug substance is an active ingredient that is intended                                                                                 |
| Efficacy                                                   | Efficacy supplement is a supplement to an approved NDA                                                                                  |
| Agency                                                     | FDA or  Agency  is the Food and Drug Administration.                                                                                    |
| First                                                      | First applicant is an ANDA applicant that, on the                                                                                       |
| Inactive                                                   | Inactive ingredient is any component other than an active                                                                               |
| Agency                                                     | or other information not previously submitted to the Agency , which may include (but is not limited                                     |
| Original                                                   | Original application or original NDA is a pending NDA                                                                                   |
| Patent                                                     | Patent owner is the owner of the patent for                                                                                             |
| Postmark                                                   | Postmark is an independently verifiable evidentiary record of the                                                                       |
| U.S                                                        | For postmarks made by the  U.S . Postal Service or a designated delivery service,                                                       |
| U.S                                                        | For postmarks made by the  U.S . Postal Service or a designated delivery service,                                                       |
| Reference                                                  | Reference listed drug is the listed drug identified by                                                                                  |
| Reference                                                  | Reference standard is the drug product selected by FDA                                                                                  |
| Resubmission                                               | Resubmission , in the context of a complete response                                                                                    |
| Same                                                       | Same drug product formulation is the formulation of the                                                                                 |
| Specification                                              | Specification is the quality standard (i.e., tests, analytical procedures,                                                              |
| Strength                                                   | Strength is the amount of drug substance contained in,                                                                                  |
| Tentative                                                  | Tentative approval is notification that an NDA or ANDA                                                                                  |
| INDs                                                       | route of administration; the identification numbers of all INDs (as defined in &#167;&#8201;312.3(b) of this chapter) that              |
| United States                                              | or have a place of business within the United States , the NDA is required to contain the                                               |
| United States                                              | or have a place of business within the United States , the NDA is required to contain the                                               |
| Approval                                                   | the applicant to prepare the Summary Basis of Approval document for public disclosure (under &#167;&#8201;314.430(e)(2)(ii)) when the   |
| United States                                              | history, if any, of the drug outside the United States , including a list of the countries in                                           |
| Reference                                                  | Reference to the current edition of the U.S. Pharmacopeia                                                                               |
| U.S. Pharmacopeia                                          | Reference to the current edition of the  U.S. Pharmacopeia and the National Formulary may satisfy relevant requirements                 |
| Reference                                                  | Reference to the current edition of the U.S. Pharmacopeia                                                                               |
| U.S. Pharmacopeia                                          | Reference to the current edition of the  U.S. Pharmacopeia and the National Formulary may satisfy relevant requirements                 |
| Evidence                                                   | Evidence is also required to support the dosage and                                                                                     |
| Effectiveness                                              | Effectiveness data from other subgroups of the population of                                                                            |
| Routine                                                    | Routine submission of other patient data from uncontrolled studies                                                                      |
| English                                                    | The applicant must submit an accurate and complete English translation of each part of the NDA that                                     |
| English                                                    | The applicant must submit an accurate and complete English translation of each part of the NDA that                                     |
| English                                                    | of each original literature publication for which an English  translation is submitted.                                                 |
| U.S. Patent                                                | with respect to each patent issued by the U.S. Patent and Trademark Office that, in the opinion of                                      |
| United States                                              | or maintain a place of business within the United States , its attorney, agent, or other authorized official)                           |
| U.S. Patent                                                | within 30 days of a decision by the U.S. Patent and Trademark Office or by a Federal district                                           |
| Appeals                                                    | by a Federal district court, the Court of Appeals for the Federal Circuit, or the U.S. Supreme                                          |
| U.S                                                        | within 30 days of a decision by the U.S . Patent and Trademark Office or by a                                                           |
| U.S. Patent                                                | application, a new patent is issued by the U.S. Patent and Trademark Office that, in the opinion of                                     |
| New                                                        | &#8220;conducted or sponsored by the applicant:&#8221; (i) &#8220; New clinical investigations.&#8221; A certification that to the best |
| Purchase                                                   | Purchase of nonexclusive rights to a clinical investigation after                                                                       |
| Electronic                                                 | Electronic format submissions must be in a form that                                                                                    |
| U.S. Patent                                                | or its representative may be obtained from the U.S. Patent  and Trademark Office; and                                                   |
| United States                                              | or maintain a place of business within the United States , the NDA holder's attorney, agent, or other                                   |
| Rockville, MD                                              | Staff, Office of Generic Drugs, 7620 Standish Pl., Rockville, MD 20855, or to the Orange Book Staff at                                  |
| Agency                                                     | notice itself need not be submitted to the Agency .                                                                                     |
| United States                                              | or have a place of business in the United States , the name and address of an agent                                                     |
| United States                                              | or have a place of business in the United States , the name and address of an agent                                                     |
| Agency                                                     | notice itself need not be submitted to the Agency .                                                                                     |
| United States                                              | Is available to the general public throughout the United States ; (ii) Records electronically to its database, kept                     |
| United States                                              | Is available to the general public throughout the United States ; (ii) Records electronically to its database, kept                     |
| Process                                                    | Process patents, patents claiming packaging, patents claiming metabolites, and                                                          |
| Test                                                       | (2)  Test data for submission of patent information for patents                                                                         |
| Strength                                                   | drug; (D) Active ingredient(s) of new drug; (E) Strength (s) of new drug;                                                               |
| U.S                                                        | drug for prescription use or over-the-counter use; (G) U.S . patent number, issue date, and expiration date                             |
| United States                                              | or maintains a place of business within the United States authorized to receive notice of patent certification under                    |
| United States                                              | or maintains a place of business within the United States authorized to receive notice of patent certification under                    |
| Patent                                                     | Patent information must also be submitted for patents issued                                                                            |
| Strength                                                   | drug; (D) Active ingredient(s) of new drug; (E) Strength (s) of new drug; (F) Dosage form(s) and                                        |
| U.S                                                        | (G) Approval date of NDA or supplement; (H) U.S . patent number, issue date, and expiration date                                        |
| United States                                              | or maintains a place of business within the United States authorized to receive notice of patent certification under                    |
| United States                                              | or maintains a place of business within the United States authorized to receive notice of patent certification under                    |
| Research                                                   | Central Document Room, Center for Drug Evaluation and Research , Food and Drug Administration, 5901-B Ammendale Rd.,                    |
| Beltsville, MD                                             | Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266, or to FDA in an electronic format              |
| Research                                                   | Central Document Room, Center for Drug Evaluation and Research , Food and Drug Administration, 5901-B Ammendale Rd.,                    |
| Beltsville, MD                                             | Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266, or to FDA in an electronic format              |
| Patent                                                     | Patent information will be considered to be submitted to                                                                                |
| Rockville, MD                                              | Room, Attention: Orange Book Staff, 7620 Standish Pl., Rockville, MD 20855, or to the Orange Book Staff at                              |
| Research                                                   | Central Document Room, Center for Drug Evaluation and Research , Food and Drug Administration, 5901-B Ammendale Rd.,                    |
| Beltsville, MD                                             | Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD  20705-1266.                                               |
| Pediatric                                                  | Pediatric  use information.                                                                                                             |
| Change                                                     | Change  in ownership of an application.                                                                                                 |
| Adverse                                                    | Adverse  drug experience.                                                                                                               |
| Individual                                                 | Individual  case safety report (ICSR).                                                                                                  |
| Disability                                                 | Disability .                                                                                                                            |
| Serious                                                    | Serious  adverse drug experience.                                                                                                       |
| Important                                                  | Important medical events that may not result in death,                                                                                  |
| Unexpected                                                 | Unexpected  adverse drug experience.                                                                                                    |
| Unexpected                                                 | &#8220; Unexpected ,&#8221; as used in this definition, refers to                                                                       |
| Followup                                                   | Followup information to adverse drug experiences submitted in a                                                                         |
| ICSRs                                                      | ICSRs  must only be submitted to FDA once.                                                                                              |
| Unique                                                     | an initial report or followup report; and (viii) Unique case identification number, which must be the same                              |
| U.S                                                        | within 60 days of the anniversary date of U.S . approval of the application, two copies of                                              |
| U.S                                                        | the annual reporting interval that ends on the U.S . anniversary date.                                                                  |
| Research, Office                                           | and Drug Administration, Center for Drug Evaluation and Research, Office  of New Drug Quality Assessment, Bldg.                         |
| New Drug Quality Assessment                                | Center for Drug Evaluation and Research, Office of New Drug Quality Assessment , Bldg.                                                  |
| Electronic                                                 | Electronic format submissions must be in a form that                                                                                    |
| Chemistry                                                  | (iv)  Chemistry , manufacturing, and controls changes.                                                                                  |
| Review                                                     | Review articles, papers describing the use of the drug                                                                                  |
| U.S                                                        | (4) Date of  U.S . approval of NDA or ANDA.                                                                                             |
| U.S                                                        | the study's status on the anniversary date of U.S . approval of the application or other agreed                                         |
| United States                                              | disruption in supply of that drug in the United States if: (1) The drug product is life supporting,                                     |
| Drug                                                       | Drug shortage or shortage means a period of time                                                                                        |
| United States                                              | or projected demand for the drug within the United States  exceeds the supply of the drug.                                              |
| Life                                                       | Life supporting or life sustaining means a drug product                                                                                 |
| Drug                                                       | Drug  products for which abbreviated applications may be submitted.                                                                     |
| Documents, U.S. Government Printing Office, Washington, DC | The list is available from the Superintendent of  Documents, U.S. Government Printing Office, Washington, DC  20402, 202-783-3238.      |
| Petition                                                   | Petition  to request a change from a listed drug.                                                                                       |
| Such                                                       | Such information may be contained in published or unpublished                                                                           |
| Agency                                                     | any bioavailability or bioequivalence testing required by the Agency , or any other information required by the                         |
| Agency                                                     | any bioavailability or bioequivalence testing required by the Agency , or any other information required by the                         |
| U.S. Patent                                                | with respect to each patent issued by the U.S. Patent and Trademark Office that, in the opinion of                                      |
| United States                                              | or maintain a place of business within the United States , its attorney, agent, or other authorized official)                           |
| U.S. Patent                                                | within 30 days of a decision by the U.S. Patent and Trademark Office or by a Federal district                                           |
| Appeals                                                    | by a Federal district court, the Court of Appeals for the Federal Circuit, or the U.S. Supreme                                          |
| U.S                                                        | within 30 days of a decision by the U.S . Patent and Trademark Office or by a                                                           |
| U.S. Patent                                                | ANDA, a new patent is issued by the U.S. Patent and Trademark Office that, in the opinion of                                            |
| Electronic                                                 | Electronic format submissions must be in a form that                                                                                    |
| U.S. Patent                                                | or its representative may be obtained from the U.S. Patent  and Trademark Office; and                                                   |
| United States                                              | or maintain a place of business within the United States , the NDA holder's attorney, agent, or other                                   |
| Rockville, MD                                              | Staff, Office of Generic Drugs, 7620 Standish Pl., Rockville, MD 20855 or to the Orange Book Staff at                                   |
| Agency                                                     | notice itself need not be submitted to the Agency .                                                                                     |
| United States                                              | or have a place of business in the United States , the name and address of an agent                                                     |
| United States                                              | or have a place of business in the United States , the name and address of an agent                                                     |
| Agency                                                     | notice itself need not be submitted to the Agency .                                                                                     |
| United States                                              | Is available to the general public throughout the United States ; (ii) Records electronically to its database, kept                     |
| United States                                              | Is available to the general public throughout the United States ; (ii) Records electronically to its database, kept                     |
| English                                                    | ANDA does not contain an accurate and complete English translation of each part of the NDA or                                           |
| English                                                    | ANDA does not contain an accurate and complete English translation of each part of the NDA or                                           |
| Such                                                       | Such communication may take the form of telephone conversations,                                                                        |
| Dispute                                                    | Dispute  resolution.                                                                                                                    |
| Appropriate                                                | Appropriate issues to raise with the ombudsman include resolving                                                                        |
| Such                                                       | Such approval will be conditioned upon the applicant incorporating                                                                      |
| U.S                                                        | application based solely on foreign clinical data meeting U.S . criteria for marketing approval may be approved                         |
| U.S                                                        | application based solely on foreign clinical data meeting U.S . criteria for marketing approval may be approved                         |
| U.S                                                        | application based solely on foreign clinical data meeting U.S . criteria for marketing approval may be approved                         |
| Failure                                                    | Failure of an application to meet any of these                                                                                          |
| Agency                                                     | applicant must receive an approval letter from the Agency .                                                                             |
| Tentative                                                  | Tentative approval of an NDA or ANDA does not                                                                                           |
| Agency                                                     | and cannot, absent an approval letter from the Agency , result in an approval under paragraph (b)(3)                                    |
| New                                                        | New  drug product exclusivity.                                                                                                          |
| Bioavailability                                            | Bioavailability study means a study to determine the bioavailability                                                                    |
| Purchase                                                   | Purchase of nonexclusive rights to a clinical investigation after                                                                       |
| New                                                        | New chemical entity means a drug that contains no                                                                                       |
| New                                                        | New clinical investigation means an investigation in humans the                                                                         |
| Request                                                    | (3)  Request  opportunity for hearing.                                                                                                  |
| Policy                                                     | submit the request to the Associate Director for Policy , Center for Drug Evaluation and Research, Food                                 |
| Research                                                   | Director for Policy, Center for Drug Evaluation and Research , Food and Drug Administration, 10903 New Hampshire                        |
| United States                                              | has been voluntarily withdrawn from sale in the United States must be accompanied by a petition seeking a                               |
| Certain                                                    | (d)  Certain drug products approved for safety and effectiveness that                                                                   |
| Refusal                                                    | Refusal  to approve an NDA.                                                                                                             |
| Health                                                     | authorized officer or employee of the Department of Health and Human Services an adequate opportunity to inspect                        |
| Health                                                     | authorized officer or employee of the Department of Health and Human Services or refuses to submit reserve                              |
| Adequate                                                   | Adequate  and well-controlled studies.                                                                                                  |
| Active                                                     | Active treatment trials usually include randomization and blinding of                                                                   |
| Isolated                                                   | Isolated case reports, random experience, and reports lacking the                                                                       |
| Refusal                                                    | Refusal  to approve an ANDA.                                                                                                            |
| Health                                                     | authorized officer or employee of the Department of Health and Human Services or refuses to submit reserve                              |
| Health                                                     | of the following apply: (1) The Secretary of Health and Human Services has suspended the approval of                                    |
| Health                                                     | authorized officer or employee of the Department of Health and Human Services or refuses to submit reserve                              |
| Rockville, MD                                              | 1-23, 12420 Parklawn Dr.,  Rockville, MD  20857, promptly upon receipt in that office.                                                  |
| Health                                                     | (1) The Secretary of the Department of  Health and Human Services, under the imminent hazard authority                                  |
| Rockville, MD                                              | and Drug Administration, room 1-23, 12420 Parklawn Dr., Rockville, MD  20857.                                                           |
| Removal                                                    | Removal  of a drug product from the list.                                                                                               |
| Adulteration                                               | Adulteration  and misbranding of an approved drug.                                                                                      |
| Research                                                   | Director of the Center for Drug Evaluation and Research , Food and Drug Administration, will give the                                   |
| New Drugs                                                  | a notice by writing to the Division of New Drugs and Labeling Compliance, Office of Compliance, Center for                              |
| Research                                                   | Office of Compliance, Center for Drug Evaluation and Research , Food and Drug Administration, 10903 New Hampshire                       |
| Rockville, MD                                              | 1061,  Rockville, MD 20852, (i) within 30 days after the date                                                                           |
| Food                                                       | (c)(1)(ii) of this section and the Commissioner of Food and Drugs will make an administrative determination on                          |
| Research                                                   | Director of the Center for Drug Evaluation and Research , Food and Drug Administration, will prepare an                                 |
| Food                                                       | submitted to the Office of the Commissioner of Food  and Drugs for review and decision.                                                 |
| Failure                                                    | Failure to so move constitutes a waiver of the                                                                                          |
| Health                                                     | The Office of the General Counsel, Department of  Health and Human Services, will observe the same separation                           |
| Judicial                                                   | Judicial  review.                                                                                                                       |
| Food                                                       | (a) The Commissioner of  Food  and Drugs will certify the transcript and record.                                                        |
| United States                                              | not a hearing has been held, in a United States court of appeals under section 505(h) of the                                            |
| United States                                              | A new drug may be imported into the United States if: (i) It is the subject of an                                                       |
| United States                                              | a new drug may be imported into the United States if it complies with the labeling exemption in                                         |
| Drug                                                       | Drug  master files.                                                                                                                     |
| Beltsville                                                 | Staff, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville , MD 20705-1266.)                                                 |
| Availability                                               | Availability for public disclosure of data and information in                                                                           |
| Docket Number                                              | application that was required to be filed in Docket Number 95S-0158 in the Division of Dockets Management (HFA-305),                    |
| Rockville, MD                                              | 1061,  Rockville, MD 20852, for investigations involving an exception from informed                                                     |
| Washington, DC                                             | Evaluations,&#8221; is available from the Government Printing Office, Washington, DC  20402.                                            |
| Approval                                                   | after July 1, 1975, a Summary Basis of Approval (SBA) document that contains a summary of the                                           |
| Beltsville, MD                                             | to the Central Document Room, 5901-B Ammendale Rd., Beltsville, MD  20705-1266.                                                         |
| Amendments                                                 | Amendments , supplements, resubmissions, requests for waivers, and other                                                                |
| Beltsville, MD                                             | filed should be addressed to 5901-B Ammendale Rd., Beltsville, MD  20705-1266, to the attention of the appropriate division.            |
| Research                                                   | Generic Drugs (HFD-600), Center for Drug Evaluation and Research , Food and Drug Administration, Metro Park North                       |
| Rockville, MD                                              | Administration, Metro Park North VII, 7620 Standish Pl., Rockville, MD  20855.                                                          |
| Correspondence                                             | Correspondence not associated with an abbreviated application should be                                                                 |
| Research                                                   | of Generic Drugs, Center for Drug Evaluation and Research , Food and Drug Administration, Attn: [insert name                            |
| Rockville, MD                                              | 150,  Rockville, MD  20855.                                                                                                             |
| Chemistry                                                  | HFD-600, the mail codes for the Divisions of Chemistry I, II, and III are HFD-620, HFD-640, and                                         |
| Bioequivalence                                             | and the mail code for the Division of Bioequivalence  is HFD-650.                                                                       |
| Policy                                                     | should be directed to the Associate Director for Policy  (HFD-5).                                                                       |
| Research                                                   | and Drug Administration, Center for Biologics Evaluation and Research , Document Control Center, 10903 New Hampshire Ave.,              |
| Rm                                                         | 71,  Rm .                                                                                                                               |
| G112                                                       | G112 , Silver Spring, MD 20993-0002, except applicants shall                                                                            |
| Research, ATTN                                             | application to the Center for Biologics Evaluation and Research, ATTN : Director, at the same address.                                  |
| Guidance                                                   | Guidance  documents.                                                                                                                    |
| Research                                                   | (b) The Center for Drug Evaluation and  Research (CDER) maintains a list of guidance documents that                                     |
| Research                                                   | of Drug Information, Center for Drug Evaluation and Research , Food and Drug Administration, 10903 New Hampshire                        |
| Scope                                                      | Scope .                                                                                                                                 |
| Approval                                                   | Approval based on a surrogate endpoint or on an                                                                                         |
| Approval                                                   | Approval under this section will be subject to the                                                                                      |
| Approval                                                   | Approval  with restrictions to assure safe use.                                                                                         |
| Withdrawal                                                 | Withdrawal  procedures.                                                                                                                 |
| Food                                                       | provide advice and recommendations to the Commissioner of Food  and Drugs.                                                              |
| Drug                                                       | Drug products approved under this program are subject to                                                                                |
| Scope                                                      | Scope .                                                                                                                                 |
| Approval                                                   | Approval based on evidence of effectiveness from studies in                                                                             |
| Such                                                       | Such postmarketing studies would not be feasible until an                                                                               |
| Withdrawal                                                 | Withdrawal  procedures.                                                                                                                 |
| Research                                                   | Director of the Center for Drug Evaluation and Research (CDER) will give the applicant notice of an                                     |
| Food                                                       | provide advice and recommendations to the Commissioner of Food  and Drugs.                                                              |
| Food                                                       | The Commissioner of  Food and Drugs' decision constitutes final agency action from                                                      |
| Drug                                                       | Drug products approved under this subpart are subject to                                                                                |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2018-03-01 | PART 314â€”APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2010-01-25 | The first annual report submitted on or after January 25, 2010 must include the information listed in this paragraph for any authorized generic drug that was marketed during the time period covered by an annual report submitted after January 1, 1999.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1999-01-01 | The first annual report submitted on or after January 25, 2010 must include the information listed in this paragraph for any authorized generic drug that was marketed during the time period covered by an annual report submitted after January 1, 1999.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1971-02-01 | (3) Disposition of patent litigation&#8212;(i) Approval upon expiration of 30-month period or 71/2 years from date of listed drug approval.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1971-02-01 | (A) Except as provided in paragraphs (b)(3)(ii) through (viii) of this section, if, with respect to patents for which required information was submitted under &#167;&#8201;314.53 before the date on which the 505(b)(2) application or ANDA was submitted to FDA (excluding an amendment or supplement to the 505(b)(2) application or ANDA), the applicant certifies under &#167;&#8201;314.50(i) or &#167;&#8201;314.94(a)(12) that the relevant patent is invalid, unenforceable, or will not be infringed, and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement within 45 days of receipt of the notice of certification from the applicant under &#167;&#8201;314.52 or &#167;&#8201;314.95, the 505(b)(2) application or ANDA may be approved 30 months after the later of the date of the receipt of the notice of certification by any owner of the listed patent or by the NDA holder (or its representative(s)) unless the court has extended or reduced the period because of a failure of either the plaintiff or defendant to cooperate reasonably in expediting the action; or |
|            |               (B) If the patented drug product qualifies for 5 years of exclusive marketing under &#167;&#8201;314.108(b)(2) and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement during the 1-year period beginning 4 years after the date of approval of the patented drug and within 45 days of receipt of the notice of certification from the applicant under &#167;&#8201;314.52 or &#167;&#8201;314.95, the 505(b)(2) application or ANDA may be approved at the expiration of the 71/2 years from the date of approval of the NDA for the patented drug product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1971-02-01 | If before the expiration of the 30-month period, or 71/2 years where applicable, the district court decides that the patent is invalid, unenforceable, or not infringed (including any substantive determination that there is no cause of action for patent infringement or invalidity), the 505(b)(2) application or ANDA may be approved on:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (A) The date on which the court enters judgment reflecting the decision; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (B) The date of a settlement order or consent decree signed and entered by the court stating that the patent that is the subject of the certification is invalid, unenforceable, or not infringed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 1971-02-01 | If before the expiration of the 30-month period, or 71/2 years where applicable, the district court decides that the patent has been infringed, and if the judgment of the district court is appealed, the 505(b)(2) application or ANDA may be approved on:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (A) The date on which the mandate is issued by the court of appeals entering judgment that the patent is invalid, unenforceable, or not infringed (including any substantive determination that there is no cause of action for patent infringement or invalidity); or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (B) The date of a settlement order or consent decree signed and entered by the court of appeals stating that the patent that is the subject of the certification is invalid, unenforceable, or not infringed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1971-02-01 | If before the expiration of the 30-month period, or 71/2 years where applicable, the district court decides that the patent has been infringed, and if the judgment of the district court is not appealed or is affirmed, the 505(b)(2) application or ANDA may be approved no earlier than the date specified by the district court in an order under 35 U.S.C. 271(e)(4)(A).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 1971-02-01 | If before the expiration of the 30-month period, or 71/2 years where applicable, the district court grants a preliminary injunction prohibiting the applicant from engaging in the commercial manufacture or sale of the drug product until the court decides the issues of patent validity and infringement, and if the court later decides that:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (A) The patent is invalid, unenforceable, or not infringed, the 505(b)(2) application or ANDA may be approved as provided in paragraph (b)(3)(ii) of this section; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (B) The patent is infringed, the 505(b)(2) application or ANDA may be approved as provided in paragraph (b)(3)(iii) or (iv) of this section, whichever is applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1971-02-01 | If before the expiration of the 30-month period, or 71/2 years where applicable, the patent owner or the exclusive patent licensee (or their representatives) agrees in writing that the 505(b)(2) application or ANDA may be approved any time on or after the date of the consent, approval may be granted on or after that date.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1971-02-01 | (vii) Court order terminating 30-month or 71/2-year period.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1971-02-01 | If before the expiration of the 30-month period, or 71/2 years where applicable, the court enters an order requiring the 30-month or 71/2-year period to be terminated, the 505(b)(2) application or ANDA may be approved in accordance with the court's order.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1971-02-01 | If before the expiration of the 30-month period, or 71/2 years where applicable, the court enters an order requiring the 30-month or 71/2-year period to be terminated, the 505(b)(2) application or ANDA may be approved in accordance with the court's order.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1971-02-01 | If before the expiration of the 30-month period, or 71/2 years where applicable, the court(s) enter(s) an order of dismissal, with or without prejudice, without a finding of infringement in each pending suit for patent infringement brought within 45 days of receipt of the notice of paragraph IV certification sent by the 505(b)(2) or ANDA applicant, the 505(b)(2) application or ANDA may be approved on or after the date of the order.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1971-02-01 | (1) The applicant must submit the following information to FDA, as applicable:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (i) A copy of any judgment by the court (district court or mandate of the court of appeals) or settlement order or consent decree signed and entered by the court (district court or court of appeals) finding a patent described in paragraph (b)(3) of this section invalid, unenforceable, or not infringed, or finding the patent valid and infringed;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (ii) Written notification of whether or not any action by the court described in paragraph (e)(1)(i) of this section has been appealed within the time permitted for an appeal;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (iii) A copy of any order entered by the court terminating the 30-month or 71/2-year period as described in paragraph (b)(3)(i), (ii), (vii), or (viii) of this section;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|            |               (iv) A copy of any written consent to approval by the patent owner or exclusive patent licensee described in paragraph (b)(3)(vi) of this section;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (v) A copy of any preliminary injunction described in paragraph (b)(3)(v) of this section, and a copy of any subsequent court order lifting the injunction; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (vi) A copy of any court order pursuant to 35 U.S.C. 271(e)(4)(A) ordering that a 505(b)(2) application or ANDA may be approved no earlier than the date specified (irrespective of whether the injunction relates to a patent described in paragraph (b)(3) of this section).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 1962-10-10 | Approved under section 505(b) means an NDA submitted under section 505(b) and approved on or after October 10, 1962, or an application that was &#8220;deemed approved&#8221; under section 107(c)(2) of Public Law 87-781.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1984-09-24 | (2) If a drug product that contains a new chemical entity was approved after September 24, 1984, in an NDA submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act, no person may submit a 505(b)(2) application or ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act for a drug product that contains the same active moiety as in the new chemical entity for a period of 5 years from the date of approval of the first approved NDA, except that the 505(b)(2) application or ANDA may be submitted after 4 years if it contains a certification of patent invalidity or noninfringement described in &#167;&#8201;314.50(i)(1)(i)(A)(4) or &#167;&#8201;314.94(a)(12)(i)(A)(4).                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1984-09-24 | (4) If an NDA:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (i) Was submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (ii) Was approved after September 24, 1984;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (iii) Was for a drug product that contains an active moiety that has been previously approved in another NDA under section 505(b) of the Federal Food, Drug, and Cosmetic Act; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (iv) Contained reports of new clinical investigations (other than bioavailability studies) conducted or sponsored by the applicant that were essential to approval of the application, for a period of 3 years after the date of approval of the application, the Agency will not approve a 505(b)(2) application or an ANDA for the conditions of approval of the NDA, or an ANDA submitted pursuant to an approved petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act that relies on the information supporting the conditions of approval of an original NDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1984-09-24 | (5) If a supplemental NDA:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (i) Was approved after September 24, 1984; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (ii) Contained reports of new clinical investigations (other than bioavailability studies) that were conducted or sponsored by the applicant that were essential to approval of the supplemental NDA, for a period of 3 years after the date of approval of the supplemental application, the Agency will not approve a 505(b)(2) application or an ANDA for a change, or an ANDA submitted pursuant to an approved petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act that relies on the information supporting a change approved in the supplemental NDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1984-09-24 | (d) Certain drug products approved for safety and effectiveness that were no longer marketed on September 24, 1984, are not included in the list.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 2050-05-01 | (3) Each person requesting a hearing shall submit an analysis of the data upon which the person relies, except that the required information relating either to safety or to effectiveness may be omitted if the notice of opportunity for hearing does not raise any issue with respect to that aspect of the drug; information on compliance with &#167;&#8201;300.50 may be omitted if the drug product is not a combination drug product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1938-06-25 | A notice of appearance and request for a hearing under paragraph (c)(1)(i) of this section is required to contain any contention that the product is not a new drug because it is generally recognized as safe and effective within the meaning of section 201(p) of the act, or because it is exempt from part or all of the new drug provisions of the act under the exemption for products marketed before June 25, 1938, contained in section 201(p) of the act or under section 107(c) of the Drug Amendments of 1962, or for any other reason.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1938-06-25 | (2) A contention that a drug product is exempt from part or all of the new drug provisions of the act under the exemption for products marketed before June 25, 1938, contained in section 201(p) of the act, or under section 107(c) of the Drug Amendments of 1962, is required to be supported by evidence of past and present quantitative formulas, labeling, and evidence of marketing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 2018-05-06 | (b) A manufacturer or distributor of an identical, related, or similar drug product under &#167;&#8201;310.6 may seek judicial review of an order withdrawing approval of a new drug application, whether or not a hearing has been held, in a United States court of appeals under section 505(h) of the act.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 1975-07-01 | The summaries consist of the following:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|            |               (i) For an application approved before July 1, 1975, internal agency records that describe safety and effectiveness data and information, for example, a summary of the basis for approval or internal reviews of the data and information, after deletion of the following:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (a) Names and any information that would identify patients or test subjects or investigators.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1975-07-01 | (ii) For an application approved on or after July 1, 1975, a Summary Basis of Approval (SBA) document that contains a summary of the safety and effectiveness data and information evaluated by FDA during the drug approval process.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |


